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Summary 
Introduction 
Squamous cell carcinoma of the auricle has an unusually high rate 
of lymph node metastases when compared to similar tumours at 
other sites. The lymph nodes affected are close to the base of the 
skull and in the neck. Development of metastasis carries a poor 
prognosis  and  most  patients  will  subsequently  die  of  failure  of 
loco-regional  control.  Despite  the  likelihood of  a  poor  outcome 
nothing  can  be  done  for  patients  prior  to  development  of 
metastasis, as the risk of spread is not sufficiently high to warrant 
intervention in all patients. They are therefore treated with a ‘wait 
and see policy’ and only offered treatment once clinical evidence 
of metastatic spread is detected.  
This thesis sets out to examine what can be done, at the time of 
initial presentation with an auricular squamous cell carcinoma to 
identify patients who would benefit from treatment to the regional 
lymph node basins. 
Materials and Methods 
The thesis is divided into four separate studies. A systematic review 
examines  the  evidence  available  to  date,  an  anatomical  study 
examines  the  lymphatic  drainage  of  the  auricle  in  cadavers,  a 
sentinel  lymph  node  biopsy  study  examines  the  use  of  this 
technique  to  identify  early  tumour  spread  and  a  retrospective 
analysis of cases of auricular squamous cell carcinoma in our unit 
examines  histopathological  prognostic  indictors  of  metastatic 
spread. 
Results 
The systematic review found that these tumours have a metastatic 
rate of about 11%. Patients developing metastasis usually die from   4 
failure of loco-regional control. Depth of tumour invasion, tumour 
size  and  mode  of  invasion  seem  to  be  potential  indicators  of 
metastatic  risk.  There  is  a  strong  argument  for  prophylactic 
intervention to the regional lymph nodes but there is no consensus 
of opinion as to when this should be carried out  
The  anatomical  study  comprised  5  cadaveric  dissections.  They 
showed that the first echelon nodes draining the auricle lie in the 
superficial  parotid  gland,  post-auricular/  mastoid  nodal  group 
and level II of the neck. There are anastamotic pathways around 
the mastoid and post-auricular nodes that could permit embolic 
tumour cells to bypass them. Five lymphatic pathways draining the 
auricle  are  described  and  some  of  these  lie  on  the  lateral  and 
anterior surfaces of the mastoid bone and traverse the insertion of 
sternocleidomastoid. 
28 cases of auricular squamous cell carcinoma were enrolled for 
sentinel lymph node biopsy. None of them were found to have any 
metastatic spread. One case showed non-viable tumour cells in a 
lymph node. There was a high incidence of complications (14%) 
directly related to the sentinel node biopsy procedure. 
The  retrospective  analysis  identified  229  cases  of  auricular 
squamous cell carcinoma treated in our unit from 1992 - 2004. 
212  of  these  cases  had  the  primary  pathology  available  for 
analysis. 24 (of 212) patients developed metastasis. 17 patients 
died as a result of their disease usually due to failure of control at 
the regional lymph node basin. Primary tumours with a depth of 
invasion greater than 8mm have metastatic rate of 56%. Tumours 
with  a  depth  of  invasion  between  2-8mm  and  evidence  of 
cartilage destruction, lymphovascular invasion or a non-cohesive 
invasive  front  have  24%  metastatic  rate.  Tumours  outwith  these 
high-risk groups did not metastasise.   5 
Conclusions 
Elective lymph node dissections of the superficial parotid gland, 
post-auricular/mastoid and level II nodes should be considered in 
patients with primary auricular squamous cell carcinomas with a 
depth of invasion >8mm or a depth of invasion between 2 - 8 
mm and evidence of cartilage destruction, lymphatic invasion or a 
non-cohesive invasive front. This should ideally be done as part of 
an observational study to evaluate the cost / benefit ratio for these 
patients.  
The  neck  dissection  must  clear  the  mastoid  bone  to  a  sub-
periosteal level on its anterior and lateral surfaces. This will require 
the removal of the upper portion of sternocleidomastoid. 
Sentinel lymph node biopsy requires further study to evaluate it as 
a  method  for  early  detection  of  metastatic  spread  in  auricular 
squamous  cell  carcinoma.  This  could  be  done  as  part  of  an 
observational study of elective neck dissections. 
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General Introduction 
The need for the research that this thesis encompasses was born 
out of clinical experience in Canniesburn Plastic Surgery Unit. This 
unit  frequently  deals  with  patients  who  have  Squamous  Cell 
Cancer of the Auricle and some of these are unfortunate enough 
to  develop  lymph  node  metastases.  This  is  not  an  unusual 
development following many forms of cancer but it is rare from 
cutaneous  squamous  cell  carcinoma.  The  auricle  has  however 
been noted by many to be a site from which cutaneous squamous 
cell cancer is more likely to spread to the regional lymph nodes 
although the reasons for this are not clear.
1-3 The treatment for 
spread of the cancer to the regional lymph nodes is often surgical 
in the form of a lymphadenectomy procedure or neck dissection as 
it  more  commonly  known.  This  can  often  be  curative  provided 
surgical  resection  is  complete  and  no  disease  is  left  behind. 
Radiotherapy can be used in place of or as an adjunct to surgery 
in some cases.
4-6 
Surgical  resection  of  lymph  node  metastases  from  auricular 
squamous  cell  carcinoma  is  complicated  by  the  location  of  the 
lymph nodes to which it spreads. They are located in the post-
auricular, mastoid, parotid and upper cervical lymph node basins. 
They are anatomically very close to the base of the skull, temporo-
mandibular joint, the facial nerve, the internal jugular vein and the 
internal carotid artery. Their proximity to these structures means 
that resection of the lymph nodes can be difficult at best and life-
threatening  at  worst.  All  too  often  spread  of  the  cancer  to  the 
lymph nodes is not detected until the tumour has grown out of the 
lymph node and invaded the adjacent tissues. At this point surgical 
resection becomes much more complicated as in order to achieve 
loco-regional control of the disease, all invaded structures must be   16 
removed  whether  it  be  nerve  vessel  or  bone.  This  has  lead  to 
descriptions in published literature of massive resections for these 
tumours  involving  the  temporal  bone,  mandible  and  associated 
soft  tissue  structures.
7  Such  surgery  is  obviously  a  major 
undertaking  and  causes  significant  morbidity  to  any  patient 
undergoing  such  a  procedure.  Unfortunately  in  many  patients 
because of the extent of disease it is not possible to achieve loco-
regional  control  with  surgery  and  post-operative  radiotherapy. 
Treatment  of  these  patients  therefore  becomes  palliative. 
Squamous cell carcinoma of the auricle is more common in the 
elderly  population  where  other  medical  conditions,  particularly 
cardiac and respiratory, are also common. This compounds the 
problem of treatment of established metastasis. 
It would be preferable if the spread of the disease to the lymph 
nodes  could  either  be  predicted  or  detected  before  invasion  of 
important structures had occurred. This would allow for treatment 
of the lymph node basins only in those patients who would most 
benefit from it and would not require as extensive a resection as is 
required  once  disease  had  become  established.  Such  treatment 
could be in the form of an elective neck dissection or radiotherapy 
which is effective in the treatment of early metastatic spread.
5, 6 
The  following  pages  show  a  series  of  photos  of  a  patient  who 
developed  local  recurrence  and  lymph  node  metastases  from  a 
primary  auricular  squamous  cell  carcinoma.  (Figures  1-5)  The 
patient  underwent  an  extensive  resection  and  was  given  post-
operative radiotherapy to try to contain the disease. Unfortunately 
he developed an infection at the operative site, became septic and 
subsequently died during his radiotherapy treatment.   17 
 
Figure 1 - A Locally recurrent Auricular Squamous Cell 
Carcinoma  with  Metastatic  Deposits  Bulging  below  the 
Auricle   18 
 
 
Figure  2  -  The  Resected  Tissue.  Brass  tags  Indicate 
Levels of The Neck Dissection   19 
 
Figure  3  The  Resulting  Defect  showing  exposed 
Temporal Bone. The Mastoid process has been trimmed.   20 
 
Figure  4  -  A  Transverse  Rectus  Abdominus 
Myocutaneous Flap used to reconstruct the defect.   21 
 
Figure 5 - The flap Inset with a plastic tube to mantain 
the neo-auditory canal   22 
General Materials and Methods 
In order to establish which patients would benefit from treatment 
to the lymph node basins at the time of initial presentation four 
separate studies were conceived. These four studies form the next 
four chapters of this thesis. The first of these studies is a systematic 
review  conducted  to  examine  what  is  already  known  about 
metastasis  from  auricular  squamous  cell  carcinoma.  Secondly  a 
cadaveric study of auricular lymphatics examines the vessels and 
lymph nodes that drain the auricle to provide an anatomical basis 
for surgical intervention. Thirdly an interventional study examines 
the use of sentinel lymph node biopsy to detect early metastatic 
spread to the lymph nodes. Finally a retrospective analysis of all 
cases  of  auricular  squamous  cell  carcinoma  treated  in  our  unit 
over  a  12  years  period  examines  histopathological  tumour 
features as indicators of metastatic potential.  
All  four  projects  were  undertaken  at  the  same  time  and  ran 
concurrently during the research period.   23 
 
 
 
 
 
 
Prognostic Factors in Development of 
Lymph  Node  Metastases  from 
Auricular  Squamous  Cell  Carcinoma                 
A Systematic Review 
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Summary 
Review Questions 
•  What is the metastatic rate? 
•  Where and when do Metastases Develop?  
•  What is associated with Survival, Mortality and Morbidity? 
•  What indicators predict the development of metastases? 
•  Is there evidence to support targeted prophylactic therapy 
to the lymph node basins at risk of developing metastases? 
Design 
A systematic review 
Review Methods 
A database search of Medline and Embase with cross referencing 
of articles. 
Results 
The metastatic rate is 11.2% with spread to the parotid and upper 
deep  cervical  chain  most  common.  85%  of  metastases  develop 
within 12 months  and 98% within 24. Death occurs in  6.2% of 
cases  usually  due  to  failure  of  loco-regional  control.  Depth  of 
invasion,  tumour  size,  degree  of  cellular  differentiation  and 
incomplete primary excision margins may be useful in identifying 
lesions  most  at  risk  of  metastasising  but  there  is  insufficient 
evidence at present to allow targeted neck dissections.    25 
Introduction 
Background 
Lewis in 1960 was one of the first to recognise that squamous cell 
malignancy of the auricle (ASCC) has  a high metastatic rate  at 
15%.
8 Although the number of cases he reported was small (23) 
and he attached no special significance to this metastatic rate his 
findings have since been supported by several other authors with 
rates ranging from 12 to 16%.
1-3 ASCC stands apart from other 
sun induced cutaneous squamous cell carcinomas (CSCC) which 
have metastatic rates much lower at between 0.5 – 2%.
9-12 The 
reasons for this discrepancy remain unclear. SCC arising in scar 
and  at  areas  on  the  body  where  there  are  muco-cutaneous 
junctions such as the lip, anus, vulva and penis are also noted to 
have an increased risk of metastases, although the aetiology at the 
anus, vulva and penis is likely to be different.
13-15 Lewis also noted 
that  ASCC  is  the  leading  cause  of  death  in  sun-induced  non-
melanoma  skin  cancers.
14  Lymph  node  metastases  from  ASCC 
cause  particular  problems  because  they  tend  to  occur  in  lymph 
nodes located adjacent to the base of the skull and therefore can 
rapidly  involve  bone,  nerves  and  blood  vessels  making  their 
treatment  difficult  and  are  often  associated  with  significant 
morbidity and mortality.
16-20   26 
Burden of Disease 
Cutaneous  neoplasms  other  than  melanoma  are  often  not 
perceived  as  high  risk  or  life  threatening  and  there  is  marked 
variation  in  their  recording  throughout  the  UK  as  noted  by 
Goodwin.
21 It is estimated that there are over 12,000 new cases of 
non-melanoma skin cancer per year within the United Kingdom.
22 
The  reported  incidence  of  all  skin  cancers  has  been  rising 
dramatically in recent years.
23, 24 This is believed to be not only due 
to  an  increase  in  reporting  but  also  to  reflect  an  underlying 
increase in the rate due to an increase in lifetime sun exposure in 
an ageing population.
21-25 Non-melanoma skin tumours especially 
are  more  common  in  the  elderly  population  where  cumulative 
lifetime  exposure  to  sunlight  seems  to  be  an  important  risk 
factor.
15  
Iversen  and  Chuang  have  reported  that  ASCC  is  much  more 
common in men than women. In men the auricle is the site of 11 - 
25% of all CSCC and in women only 0.2 - 3%.
26,  27 The Scottish 
Cancer  Registry  obtains  information  from  patients’  discharge 
summaries,  pathology,  radiotherapy  and  oncology  departments 
throughout Scotland. Its published figures show a dramatic rise in 
the  number  of  cases  of  CSSC  from  599  in  1980  to  1741  in 
2002.
24 (Figure 6) These figures are doubtless subject to the same 
problems as elsewhere in the UK with at least part of this increase 
due to increased reporting but the totals are still likely to be an 
underestimate. 
   27 
Figure 6 - CSSC Registrations In Scotland 1980 - 2000 
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Management of Disease 
Primary malignant tumours of the external ear are treated by a 
variety of different specialities. Plastic surgeons, General surgeons, 
Dermatologists,  Otolaryngologists  and  Radiotherapists  have  all 
published series and each of them brings their own methods of 
treatment.
2, 3, 8, 16, 17, 28-45 Surgeons such as Byers, Freedlander and 
Afzelius  report  series  where  the  vast  majority  of  lesions  were 
surgically  excised.
1-3  Dermatologists  such  as  Mohs,  Ceilley  and 
Robins  favour  techniques  such  as  micrographic  surgery, 
electrodessication  and  liquid  nitrogen  ablation.
43,  46-49 
Radiotherapy has also been successfully used by authors such as 
Alexander  and  Caccialanza.
29,  34  The  various  different  methods 
have all been shown to have good rates of local tumour control 
and  Cooper  has  shown  that  postoperative  chemo-radiotherapy 
can improve this but at a significant cost to the patient.
4  
Surgical  excision  is  the  most  common  management  in  the 
published  literature  especially  in  recent  years.
2,  3,  48  It  would, 
however, be rash to assume that this means that it  is the  most 
commonly  employed  technique.  Nordin,  a  dermatologist, 
published a series in 1999 treated by curettage-cryosurgery, which 
may reflect current practice by many dermatologists.
49 There is no 
information available at present to indicate how many cases are 
treated by each speciality and what factors influence methods of 
treatment. 
Management of the regional lymph nodes basins at the time of 
initial  presentation  remains  controversial.  Alfzelius  in  1980 
published guidelines on elective lymphadenectomy based upon a 
relatively  small  series  (65  of  which  11  metastasised)  but  his 
indications  have  not  been  supported  by  Byers  and  Freedlander 
who have published larger series.
1-3 While all these authors have   29 
reported excision of lymph nodes based upon clinical evidence of 
involvement  either  at  the  time  of  initial  presentation  or 
subsequently,  Byers  and  Chen  have  performed  elective  lymph 
node  dissection  but  unfortunately  give  no  indication  of  the 
selection criteria used.
2, 36 There is evidence from several sources 
to  indicate  that  early  excision  of  CSCC  metastases  to  cervical 
nodes before multiple nodes become involved or extra-capsular 
spread has occurred confers a survival advantage but none of this 
refers specifically to auricle as the primary tumour site.
4, 13, 19, 50-54   30 
The Auricle as a Site of Malignancy 
The external ear, due to its location, is a site on the body that is 
exposed  to  sun  on  a  regular  basis.  In  females,  however,  the 
hairstyle  determines  the  level  of  sun-exposure.  Iversen,  Ceilley, 
Byers,  Freedlander  and  most  other  authors  have  noted  a  large 
male bias for auricular neoplasms with rates in females as low as 
0.2 - 3%.
3, 27, 48, 55 They also noted that the tumours usually occur in 
the  elderly,  particularly  those  with  outdoor  occupations.  These 
factors have led the authors to conclude that sun-exposure is the 
primary  aetiology  for  the  development  of  malignancy  in  most 
cases. However the types of tumour that arise on the auricle differ 
considerably from that of other sun-exposed sites. Ahmed showed 
that for the head and neck the ratio of BCC to SCC was 4:1 but 
on the auricle this drops to 1.3:1.
56 This implies that the skin of the 
auricle behaves differently under exposure to solar radiation but 
there is as yet no obvious explanation for this. 
The lymphatic drainage of this region is plentiful with at least three 
lymphatic territories draining the skin of the auricle as described in 
current anatomical textbooks based upon the work of Rouviere.
57, 
58 There is a slim anterior portion of the tragus and helical root 
that drains anteriorly to the pre-auricular nodes; posterior to this 
the territory is split into an upper and lower half with drainage to 
the post-auricular and deep cervical nodes respectively. It is easy 
to understand that a malignancy need not grow very large before 
it  overlaps  two  or  three  lymphatic  drainage  pathways  and  it  is 
possible  that  this  diffuse  lymphatic  drainage  may  contribute  to 
allowing tumour cells to spread easily. 
In addition to considering the lateral growth of the tumour it is 
important to also consider the vertical growth of the tumour. The 
lymphatics  of  the  skin  begin  just  below  the  papillary  dermis  in   31 
blind  ending  endothelial-lined  tubes  or  loops  that  drain  to  a 
superficial plexus. This plexus drains through collecting ducts to a 
deeper plexus at the base of the dermis which in turn drains into 
larger subcutaneous channels.
57 The skin on the anterior part of 
the  pinna  is  thin  and  tightly  bound  to  the  underlying  cartilage. 
Tumours  that  arise  in  the  epidermis  and  grow  vertically  down 
through  the  dermis  encounter  an  increasing  number  and 
increasing calibre of lymphatic vessel. On the pinna this distance 
is less than at other sites due to the thinness of the skin.  
The external ears are believed to play a function in the cooling of 
the  body  which  leads  them  to  have  a  disproportionately  high 
blood  flow.  Production  of  lymphatic  fluid  is  a  largely  passive 
process  caused  by  the  difference  in  hydrostatic  and  osmotic 
pressures between circulating blood and extra-cellular fluid.
59 It is 
possible that greater production of lymphatic fluid in the auricle 
could contribute to the ease with which tumour cells are carried 
away to lymph nodes from a tumour but again there is no direct 
evidence  for  this.  These  specific  anatomical  features  may  mean 
that it is useful to consider ASCC separately from other high risk 
SCC when looking for potential markers of metastatic potential. 
Melanoma is another common skin malignancy induced by solar 
damage which frequently metastasises to regional lymph nodes. 
Ravin  recently  reported  a  series  of  199  cases  of  auricular 
melanoma and reviewed previous evidence.
60 He concluded that 
with auricular melanoma the metastatic rate was greater (39.2%) 
and prognosis poorer than for other anatomical sites and that this 
was  unaffected  by  conservative  surgical  margins  that  had  been 
postulated by some as a reason. The fact that tumours from two 
different  precursor  cells  both  show  increased  metastatic  spread 
from this site supports a hypothesis that there is something specific   32 
about  the  lymphatic  drainage  of  the  auricle  that  permits  or 
encourages tumour cells to metastasise.   33 
Materials and Methods 
The aim was to find all relevant published material on the topic of 
lymph node metastasis in ASCC. A  search strategy was created 
based  upon  guidance  published  by  the  Centre  for  Reviews  and 
Dissemination, the Cochrane Library and independent articles.
61-64 
Three electronic databases were searched – Medline, Embase and 
The  Cochrane  Library.  The  reference  lists  from  any  articles  of 
relevance  found  from  these  databases  were  then  used  to  find 
further  references.  The  search  was  not  restricted  to  the  English 
language but articles would only be translated in full if a native 
language reader was able to confirm the potential usefulness of 
the article. 
The  Cochrane  Library  contained  no  relevant  material  and 
subsequent searching was confined to Medline and Embase. The 
strategy  used  was  identical  for  both  databases.  Initially  the 
databases  were  searched  for  ‘Squamous  Cell  Carcinoma’  as  a 
subject heading. Within this subset several groups of papers were 
defined.  First  all  papers  that  were  coded  under  the  subject 
heading of ‘External Ear’ as this is where all references to pinna, 
auricle  and  external  ear  should  be  placed.  Secondly  all  papers 
where the any of the words ‘pinna’, ‘auricle’ or ‘ear’ appeared in 
the title or abstract. The third and last group was papers from the 
‘Squamous  Cell  Carcinoma’  heading  also  coded  under  ‘Lymph 
node metastasis’ and had either the word ‘skin’ or ‘cutaneous’ in 
the title or abstract.  This last group was included because some 
papers  that  report  information  on  lymph  node  metastases 
subdivided their data by anatomical site thus allowing information 
on ASCC to be extracted. 
The results of this search were then read to establish papers of 
relevance.  Copies  of  these  papers  were  then  obtained  either   34 
electronically  or  photocopied  and  read.  The  references  of  each 
paper  were  checked  for  additional  papers  that  may  be  of 
relevance that had been missed by the original search. Copies of 
these were then obtained.   35 
Electronic Search Strategies  
Database: Ovid MEDLINE(R) <1966 to October Week 1 2006> 
Search Strategy: 
-------------------------------------------------------------------------------
- 
1     Carcinoma, Squamous Cell/ (76414) 
2     Ear, External/ (8147) 
3     1 and 2 (228) 
4     pinna.m_titl. (226) 
5     auricle.m_titl. (575) 
6     ear.m_titl. (17117) 
7     4 or 5 or 6 (17860) 
8     1 and 7 (249) 
9     skin.m_titl. (78416) 
10     cutaneous.m_titl. (30592) 
11     9 or 10 (107932) 
12     1 and 11 (3689) 
13     Lymphatic Metastasis/ (49475) 
14     12 and 13 (154) 
15     3 or 8 or 14 (532) 
 
***************************   36 
Database: EMBASE <1980 to 2006 Week 41> 
Search Strategy: 
-------------------------------------------------------------------------------
- 
1     Squamous Cell Carcinoma/ (32794) 
2     External Ear/ (1223) 
3     1 and 2 (41) 
4     pinna.m_titl. (163) 
5     auricle.m_titl. (328) 
6     ear.m_titl. (10771) 
7     4 or 5 or 6 (11219) 
8     1 and 7 (113) 
9     skin.m_titl. (53678) 
10     cutaneous.m_titl. (24138) 
11     9 or 10 (76934) 
12     1 and 11 (2456) 
13     Lymph Node Metastasis/ (28788) 
14     12 and 13 (77) 
15     3 or 8 or 14 (213) 
 
***************************   37 
Results 
A  total  of  735  references  were  generated  from  the  electronic 
databases. The vast majority of these were excluded by reading 
the title and or abstract. The most common reasons for exclusion 
of articles at this stage were: 
•  Articles focussing upon reconstructive techniques 
•  Reporting methods of excision only 
•  Case reports with no relevant information 
Paper or electronic copies of 87 articles were then retrieved and 
read for relevance. Unfortunately many of these could not be used 
for the following reasons: 
•  Failure to separate SCC from other tumours affecting the 
auricle 
•  Failure to separate auricular SCC from SCC at other sites 
most commonly pre- and post-auricular SCC 
Some of these papers were able to contribute information in some 
areas but not others due to the way the data had been presented. 
The reference list of each of the 87 articles was then read to look 
for further articles of interest. A total of 10  further articles were 
then obtained. No further articles were recruited by reading the 
reference list of these 10 articles.   38 
What is the metastatic rate? 
A total of eleven papers were found that provided information on 
regional metastases.
1-3, 16, 36, 38, 42, 45, 65-67 (One paper that did report 
this  was  excluded  because  it  quoted  the  total  number  of  cases 
inconsistently  (335  versus  261)  when  calculating  rates.
44)  The 
results are summarised in table 1. The overall averaged metastatic 
rate was 11.2% and for those series with a minimum follow-up 
period  of  two  years  (the  period  during  which  most  metastases 
would be likely to appear) 11.8%. A funnel plot of the metastatic 
rates  against  the  number  of  patients  is  shown  (Figure  7).  The 
specialities  of  dermatology,  general  surgery,  oncology, 
otolaryngology and plastic surgery have been represented in the 
publications.    39 
Figure 7 - Funnel Plot of Metastatic rates 
   40 
Table 1 - Summary of Metastatic Rates 
Lead 
Author 
Year 
Total 
Number 
Follow-
up 
(Months) 
Metastatic 
Rate 
(Number) 
Afzelius  1980  67  > 15  16.4%(11) 
Blake  1974  81  Unknown  12.3%(10) 
Byers  1983  486  > 24  12%(58) 
Chen  1978  17  18  9.1%(1) 
Fredricks  1956  27  Unknown  11.1%(3) 
Freedlander  1983  152  > 12  13.2%(23) 
Leferink  1988  12  6-36  25%(3) 
Lee  1996  71  >12  2.8%(2) 
Pless  1976  177  Unknown  6%(10) 
Shiffman  1975  52  15-36  13.5%(7) 
Shockley  1987  40  > 24  10%(4) 
Totals    1182    11.2%(132) 
Total for 
Follow up 
>24 
months 
  526    11.8%(62) 
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Where do Metastases Develop? 
Of  the  eleven  papers  that  gave  information  on  regional 
metastases only three gave detailed information on the frequency 
of  nodal  metastases  to  different  nodal  basins.  Two  additional 
papers that looked at lymph node metastases from all head and 
neck CSCC also provided information on location of spread from 
auricular  primaries  although  neither  of  these  papers  considered 
the post-auricular nodes as a separate group.
19,  68 (Table 2) The 
parotid  gland  and  upper  deep  cervical  chain  are  the  most 
common site of lymph node metastases.
3, 38, 55 These nodal basins 
both seem to be involved in a significant number of cases when 
regional metastases develop.
3 The post-auricular nodes are also 
frequently  involved.
2,  38  No  author  has  reported  involved  lymph 
nodes in other parts of the neck without one of these areas being 
involved.  42 
Table 2 - Location of metastatic disease 
Lead Author 
Total Number of 
Metastases  Post Auricular  Parotid 
Upper Deep 
Cervical  Neck Other Levels 
Byers  79  12  35  28  4 
Freedlander  29    14  15   
Jol  17    6  6  5 
Vauterin  49    28  8  13 
Leferink  4  1  2  1   
Total  178  13(7.3%)  85(47.8%)  58(32.6%)  22(12.4%)   43 
Survival and Mortality 
Only  two  papers  provided  information  on  survival  following 
primary diagnosis.
27, 42 One paper noted the 3.5 year survival as 
62% and 5 year survival at 55% to be only marginally shifted from 
normal  survival  for  the  population  and  another  showed  the 
relative survival rate to be 80%.
27, 42 Both papers make comment 
on the fact that the cause of death is usually other than ASCC or 
its LNM. Neither paper made any comment about patients dying 
of intercurrent disease with active tumour. Seven quoted rates of 
death attributable to disease either locally invasive or metastatic 
disease.
2, 3, 16, 38, 45, 65, 67 Most of these were relatively small numbers 
and the rates varied considerably. Byers reported a much higher 
rate of death attributable to local failure but has included parotid 
disease in this category.
2 Byers also showed a large difference in 
survival if there was more than one lymph node involved, parotid 
invasion or extra-capsular spread.
55 Despite this no difference in 
survival has been shown for those patients receiving prophylactic 
versus therapeutic lymphadenectomies.
2 Weinstock reported in a 
paper  regarding  non-melanoma  skin  cancer  in  Rhode  Island  in 
the USA that in 47% of deaths attributable to CSSC the primary 
tumour site was auricle.
69 The highest of any one site on the body.   44 
Morbidity 
It is difficult to quantify the morbidity associated with metastases 
due to the various reporting styles and emphasis of the authors. 
Byers  reports  that  twenty  patients  required  a  radical  neck 
dissection with sacrifice of the sternocleidomastoid muscle, internal 
jugular vein and XI
th cranial nerve; 46 patients required sacrifice of 
the  facial  nerve;  11  require  a  partial  mandibulectomy. 
Freedlander comments on bony involvement in six patients. (Table 
3) 
 
Table  3  -  Summary  of  Deaths  Directly  Attributable  to 
Disease 
Lead 
Author 
Total 
Number 
Died of 
Disease 
(No) 
Local 
Failure 
death rate 
(No) 
Metastatic 
death rate 
(No) 
Blake  81  9.9%(8)  1.2%(1)  8.6%(7) 
Byers  486  5.1%(25)  2.5%(12)  2%(10) 
Chen  17  5.9%(1)  5.9%(1)  0 
Fredricks  27  3.7%(1)  0  3.7%(1) 
Freedlander  152  7%(13)  0  7%(13) 
Leferink  12  8.3%(1)  0  8.3%(1) 
Shiffman  52  7.7% (4)  0  7.7% (4) 
Shockley  40  2.5%(1)  0  2.5%(1) 
Totals  867  6.2%(58)  1.6%(14)  4.2%(37) 
   45 
Time to Development of Metastases 
Five  papers  gave  information  on  the  time  to  develop  LNMs 
following primary diagnosis.
3, 36, 38, 45, 65 In most cases the majority 
of the LNMs appeared within one year. Less than 15% appeared 
after this and only 4  (1.6%) reported cases developing LNMs after 
two years. (Table 4) 
 
Table 4 - Time to Development of Metastases 
Lead Author  Total 
Number 
Number of 
Metastases 
Time to Nodal 
Mets Months 
Chen  17  2  0-42 
Fredricks  27  3  10-32 
Freedlander  152  23  2-51 
Leferink  12  3  3-27 
Shiffman  52  7  7-18 
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Does  Tumour  Size  Predict  Development  of 
Metastases? 
Freedlander  reported  that  50%  of  tumours  greater  than  3cm 
diameter  metastasised  and  that  the  mean  size  of  tumour  was 
2.8cm in patients with metastases as opposed to 1.7cm in patients 
without.
3  Afzelius  reported  that  44.4%  of  tumours  greater  than 
12cm
2    (equivalent  to
  a  3.9cm  diameter  round  tumour) 
metastasised.
1  Neither  of  these  authors  has  given  a  statistical 
significance of this. 
In contrast to this Byers, in the largest series by far, has reported 
that there is no correlation between tumour size and development 
of metastases.
2 There is no indication in the paper of the variation 
in the size of the tumours they treated. Schockley commented that 
lesions greater than 3cm diameter conferred an adverse prognosis 
but not directly on the development of LNM.
67    47 
Does Depth Of Invasion Predict Development of 
Metastases? 
Afzelius  found  that  the  Clark  level  (Table  5)  of  lesions  that 
metastasised was significantly higher than that of lesions that did 
not.
1 In that series of 36 tumours that had reached Clark level 5 
(sub-cutaneous tissue) 11 metastasised – 30.6%. This dropped off 
quickly to 1 of 10 metastasising at level 4 and 1 of 12 at level 3. 
Despite this in Freedlander’s series, which was twice as large, the 
authors looked at depth of invasion but were unable to correlate 
this  development  of  LNM.
3  Both  these  authors  also  felt  that 
cartilage invasion was an important predictor in development of 
metastases. Byers has made a blanket comment that histological 
findings did not correlate with development of metastases but has 
not specified which specific histological features this referred to.
2 
 
Table 5 - Clark's levels 
Clark’s Level  Depth of Invasion 
I  Confined to epidermis 
II  invades papillary dermis 
III  invades to papillary-reticular dermal interface 
IV  invades the reticular dermis 
V  invades subcutaneous tissue 
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Does  Mode  Of  Invasion  Predict  Development  of 
Metastases? 
Afzelius  again  showed  a  significant  difference  between  those 
tumours that had metastasised and those that had not using a four 
level scoring system of mode of invasion.
1 (Table 6) In level four 7 
of 13 metastasised 53.8%; level three 4 of 16 25%; level two 2 of 
30 6.7% and level one 0 of 10. Freedlander looked at this but 
found  that  despite  a  clear  definition  they  could  not  readily 
reproduce comment on the tumour architecture.
3  
 
Table 6 - Scoring system for Mode of Invasion used by 
Afzelius 
Score  Histological features 
1  Tumour with a well defined border 
2  Tumour with cords and a less well-marked borderline 
3  Tumour  with  groups  of  cells  and  no  distinct 
borderline 
4  Tumour with diffuse growth pattern 
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Does  the  Degree  of  Cellular  Differentiation 
Predict Development of Metastases? 
Freedlander looked at this again but found that the same problem 
of reproducibility existed and therefore this could not be reliably 
used.
3  Afzelius  noted  an  insignificant  difference  between  the 
differentiation of tumour that metastasised and those that did not.
1 
 
Does  Location  of  the  Primary  Tumour  Predict 
Development of Metastases? 
Only two papers have commented upon this and neither found 
any  significant  correlation  between  primary  tumour  site  and 
development of metastases.
2, 16 
 
Do  Excision  Margins  Predict  Development  of 
Metastases? 
Only Freedlander has commented on this and noted that 43% of 
the cases in his series who developed lymph node metastases had 
doubtful or incomplete primary excision margins.
3   50 
Is  There  Guidance  on  When  to  Prophylactically 
Treat The Lymph Node Basins? 
Afzelius believed that a tumour size greater than 12cm
2, cartilage 
invasion, depth of invasion to Clark level 5 or a maximum score 
for  mode  of  invasion  should  encourage  treatment  to  the  lymph 
nodes in the form  of a neck dissection.
1 Freedlander suggested 
that  any  tumours  greater  than  3cm  in  diameter  should  warrant 
further  therapy.
3  No  author  has  suggested  the  level  of  risk  of 
occult  metastases  that  should  exist  before  an  elective  neck 
dissection is performed. 
Several authors have commented on the debilitating nature of the 
surgery involved once the facial nerve or bone of the skull base 
become involved and the lesser potential for cure once the disease 
has reached this stage.
2, 3 
Prophylactic  versus  Therapeutic  Lymph  Node 
Dissections? 
Byers found no difference in survival if an elective neck dissection 
was performed or if a therapeutic neck dissection was performed 
but  gave  no  indication  of  how  many  patients  fell  into  these 
categories.
2  There  are  no  papers  comparing  elective  and 
therapeutic neck dissections.   51 
Discussion 
The  overall  metastatic  rate  for  ASCC  is  slightly  over  11%.  This 
figure is maintained in series that have a minimum follow up of 
two years which should account for over 98% of all metastases. 
There  is  no  bias  in  the  funnel  plot  indicating  that  the  series 
reviewed here are representative of the underlying level of disease 
in  the  population.  This  is  further  reinforced  by  the  fact  that  all 
specialities that would be expected to treat this malignancy have 
contributed to the publications. This removes any suspicion that it 
is only the more advanced cases that are being reported which 
could have led to an artificially high metastatic rate. 
The overall survival figures for the disease reflect to some degree 
the fact that the population affected by this condition are elderly. 
Those authors who reported survival figures commented upon the 
large  number  of  patients  who  died  of  intercurrent  disease  but 
despite this the disease has been directly attributed to the death in 
6.2% of cases. In the majority of cases this was due to failure of 
control at the level of local lymph node basins. 
Parotid involvement and extra-capsular spread are known to be 
adverse prognostic indicators in LNM from CSCC.
4, 13, 19, 50-54 This 
combined with the large decrease in survival noted by Byers once 
two or more nodes became involved suggests that early detection 
and treatment of LNM or prophylactic treatment is likely to confer 
a  survival  advantage.  Given  the  small  number  of  deaths 
attributable  to  this  disease  and  the  lack  of  a  controlled 
randomised trial it is not surprising that there is no direct evidence 
for this. Similarly it is not possible to directly comment upon the 
influence  that  early  treatment  of  the  lymph  node  basins  would 
have upon morbidity. Despite this LNMs must grow and spread 
outwith  the  capsule  of  the  lymph  node  before  they  can  invade   52 
structures  such  as  the  facial  nerve  and  bone.  It  is  resection  of 
structures such as these that makes curative resection difficult and 
causes permanent disability and disfigurement. 
There were several factors that seemed to be possible indicators of 
an  increased  risk  of  developing  LNM.  Unfortunately  despite 
support for these by some authors all have been contradicted by 
others.  Byers  published  the  largest  series  by  some  considerable 
margin and failed to find any pathological prognostic indicators. 
However Byers does not give any indication of the methods used 
to look for possible relationships nor any descriptive measures of 
the range of size, depth and differentiation of the tumours in the 
series.  Without  this  information  we  cannot  be  sure  that  he  has 
managed to refute the findings of the other authors. 
In a cosmetically important structure such as the auricle it is easy 
to understand why excision  margins of tumour excision  may be 
intentionally kept relatively small when compared with other sites 
on the body. Freedlander is the only author to note the possible 
link  between  incompleteness  of  primary  excision  and  the 
development  of  LNM,  even  in  the  absence  of  locally  recurrent 
disease.
3  This  emphasises  the  need  for  adequate  primary 
intervention in these tumours to prevent progression of disease.  
Freedlander and Afzelius felt that tumour size gave an indication 
of metastatic potential. Their findings suggest that tumours with a 
diameter of 3 – 3.9cm or over have a metastatic potential of over 
44%. Byers gives no indication of the number of tumours in his 
series over 3cm in diameter or 12cm
2 that would have met the 
criteria set by these other authors as high risk.  
Depth  of  invasion  (Clark  Level)  was  found  by  Afzelius  to  be  a 
significant indicator of development of metastases.
1 Freedlander is 
the  only  other  author  to  comment  on  this  and  found  no 
relationship  although  the  wording  of  the  paper  is  such  that  it   53 
would  seem  they  looked  at  cartilage  invasion  rather  than  a 
measured depth of invasion or  Clark level.  In CSSC in general 
and melanoma the depth of invasion has been shown to be one of 
the  most  significant  prognostic  indicators  in  the  development  of 
metastases.
13, 70 It would seem logical that this should also be the 
case in ASCC. 
Afzelius found a strong relationship between the mode of tumour 
invasion and development of LNM. In the scoring system used in 
his series, tumours with a diffuse growth pattern (score 4) were 
more likely to metastasise than those with a lower score and no 
tumours  with  a  well  defined  border  (score  1)  metastasised.  He 
further went on to publish a histological scoring system for cancers 
of  the  external  ear.
71  Freedlander  and  co-author  found  that 
between them they could not reliably reproduce comments upon 
the  mode  of  tumour  invasion.  This  lack  of  reproducibility  is  a 
significant problem that affects histo-pathological examination of 
ASCC, not just when examining mode of invasion but also when 
looking for degree of cellular differentiation. The use of subjective 
measures is subject to both intra- and inter-observer variation. The 
mode of invasion may vary across the invasive front of a tumour. 
Since  the  presence  of  any  area  of  an  aggressive  invasive  front 
would  be  enough  to  upgrade  a  tumour  into  an  aggressive 
category, the higher the proportion of the tumour examined will 
increase the number of aggressive tumours. Similarly an area of 
poor  differentiation  may  only  be  present  in  one  part  of  the 
specimen.  It  can  only  be  concluded  that  in  the  hands  of  one 
pathologist it may be possible to correctly identify the tumours with 
the  most  aggressive  mode  of  invasion  but  that  subjectivity  and 
resources available to examine the specimen limit use of this.  
In the 1970’s it was suggested that for a neck dissection to be 
beneficial in head and neck cancer, the risk of occult metastases   54 
should be greater than 20%.
72 More recently it has been suggested 
that this figure should be lowered to 15%.
73 These figures are for 
malignancies  of  the  upper  aero-digestive  tract  that  usually 
metastasise to lymph nodes that are more easily palpable and do 
not  invade  skull  base  or  nerves  and  can  therefore  be  detected 
earlier and resected more easily and with less morbidity. For that 
reason it would seem that 15%  should be the minimum risk  of 
occult  LNM  at  which  prophylactic  therapy  to  the  lymph  node 
basins  should  be  offered  although  a  full  cost  benefit  analysis 
would  need  to  be  carried  out  in  order  to  determine  the  exact 
threshold. It interesting to note that no-one has suggested using 
radiotherapy for prophylactic treatment of the lymph nodes despite 
its proven use in the treatment of micro-metastases.
5, 6, 74 
Sentinel lymph node biopsy is an emerging technique that is being 
used successfully in melanoma and Head and Neck squamous cell 
carcinoma  with  great  accuracy  in  determining  the  presence  of 
occult  lymph  node  metastases.
75,  76  It  is  a  technique  with  low 
morbidity  and  greater  accuracy  in  comparison  to  elective  neck 
dissections. It would therefore seem to be a potential avenue for 
further research in this field.   55 
Conclusions 
Auricular squamous cell carcinoma has a metastatic rate of 11%. 
This  is  significantly  higher  than  other  sun  induced  cutaneous 
squamous  cell  carcinomas.  It  is  associated  with  a  significant 
mortality at 6.2%, which is usually due to failure of control at the 
level of the local lymph node basins. It is likely that tumour size 
and depth of invasion are useful in  stratifying the risk of occult 
metastases  but  more  work  should  be  done  to  confirm  this.  The 
histological  parameters  of  mode  of  invasion  and  cellular 
differentiation are also likely related to risk of occult metastases 
but the difficulties associated with reproducibility and reliability of 
these subjective measures means that a great deal more evidence 
will be required from different sources to support their widespread 
use.  
Treatment  of  the  primary  tumour  should  be  thorough  and  re-
excision or other treatment should be used when there is doubt 
about the excision margins. 
It is not possible based upon the currently available evidence to 
confidently  stratify  patients  into  a  high-risk  category  where 
prophylactic  treatment  of  the  lymph  node  basins  would  be 
deemed  acceptable.  Prophylactic  treatment  of  the  lymph  node 
basins  is,  however,  likely  to  confer  a  survival  advantage  and 
reduce  morbidity  when  compared  to  therapeutic  lymph  nodes 
dissections. Prophylactic therapy should include at a minimum the 
post-auricular,  parotid  and  upper  cervical  lymph  nodes. 
Consideration should be given to the use of Sentinel Lymph Node 
Biopsy in these lesions.   56 
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Summary 
Introduction 
Cutaneous tumours of the auricle are know to have a high rate of 
spread to the regional lymph nodes and for this reason removal of 
the lymph nodes for diagnostic or therapeutic purposes is often 
required.  Recent  work  using  sentinel  node  biopsy  in  cutaneous 
tumours  of  the  head  and  neck  has  questioned  the  commonly 
described  lymphatic  pathways  that  are  believed  to  exist  and 
therefore further study is required. 
Materials and Methods 
A  cadaveric  model  with  Indian  ink  injection  of  auricles  and 
dissection and clearing of specimens. 
Results 
Five distinct pathways are displayed leaving the auricle with five 
different locations for sentinel nodes. Two of these nodal locations 
have anastamotic pathways which would permit embolic tumour 
cells  to  bypass  the  nodes.  Pathways  descend  adjacent  to  the 
mastoid  bone  periostium  and  traverse  the  origin  of  the 
sternocleidomastoid muscle. 
Conclusions 
Sentinel lymph node biopsy for cutaneous tumours of the auricle 
should be possible but the presence of skip metastases should be 
considered.  Lymphadenectomy  procedures  will  require  the 
resection of the sternocleidomastoid muscle and dissection to the 
periostium of the mastoid bone.   58 
Introduction 
Malignant  tumours  of  the  skin  of  the  auricle  are  known 
metastasise  more  commonly  than  comparable  tumours  at  other 
sites.
2,  3,  16,  30,  32,  55,  77-79  Because  of  this  prophylactic 
lymphadenectomy is seen as a potentially useful procedure as it 
allows  staging  of  the  disease  and  removes  small,  sub-clinical 
deposits  of  metastatic  disease  before  they  involve  important 
structures at the base of skull or spread further to cause distant 
metastases.
1,  3 Prognosis is known to be better in squamous cell 
carcinoma when the tumour has reached fewer nodes and has not 
yet breached the capsule surrounding each node. 
2, 3, 53 
The classical procedure to remove lymph nodes for a head and 
neck  cancer  is  the  radical  neck  dissection.  (Appendix  2 
contains  information  on  the  terminology  of  neck  dissection.) 
This procedure carries significant morbidity and because of this 
it  is  no  longer  the  favoured  procedure  for  staging  of  the 
cervical lymph nodes. Nowadays a selective node dissection is 
more popular. In this operation selected parts of the lymphatic 
chains  are  removed  and  important  structures  such  as  the 
sternocleidomastoid  muscle,  internal  jugular  vein  and 
accessory  nerve  are  preserved.  This  allows  for  staging  of 
disease  in  the  neck  and  removal  of  early  metastases  while 
minimising  morbidity.  This  change  from  radical  to  selective 
neck dissections has come about through increased knowledge 
of the likely location of metastatic disease and the lymphatic 
pathways involved and it has undoubtedly caused a decrease 
in surgical mortality  and morbidity.
73 The fact that these  are 
safer operations with less complications coupled with advances 
in  peri-operative  medical  care  has  also  meant  that  patients 
with significant other diseases can now be offered this surgery.   59 
Selective  lymph  node  dissections  have  been  successful  in  the 
treatment  of  cancers  of  the  head  and  neck  that  are  commonly 
associated  with  metastatic  spread  such  as  oral,  pharyngeal, 
laryngeal, nasal and thyroid tumours. These cancers have all been 
studied  in  detail  and  there  is  significant  information  available 
which allows specific nodes to be excised in selected nodal basins. 
Auricular tumours, however, have not been studied in such great 
detail. A comprehensive neck dissection would include a complete 
parotidectomy  in  addition  to  the  other  cervical  lymph  node 
basins.
1,  2  There  is  no  established  pattern  of  selective  nodal 
dissection for this site. This is in part due to the fact that it has 
been difficult to categorise those auricular tumours most at risk of 
developing metastases and therefore most likely to benefit from 
lymphadenectomy.  As  a  result  many  patients  are  only  offered 
treatment  if  and  when  lymphatic  deposits  of  tumour  become 
clinically detectable.
1 Even in these cases there is no consensus of 
what constitutes a comprehensive neck dissection. 
Sentinel lymph node biopsy is an emerging technique which aims 
to excise only specific lymph nodes draining a target area of tissue 
and  therefore  to  reduce  morbidity  even  further.
76  The  technique 
has progressed from the originally described method of looking 
for specific lymph nodes at predetermined locations to the modern 
technique  which  involved  dynamic  localisation  of  lymph  nodes 
pre- and intra-operatively. It relies on being able to identify target 
lymph nodes by means of a radioactively marked colloid and blue 
dye at the time of surgery. These nodes are the first lymph nodes 
that lymph from any tumour will travel to before progressing on to 
other  nodes  and  are  sometimes  referred  to  as  ‘first  echelon’ 
nodes.  Although  this  technique  makes  it  easier  to  find  target 
nodes, a sound understanding of the normal anatomical pathways 
is helpful to facilitate dissection and location of target nodes.   60 
Current textbooks on the subject of auricular lymphatic drainage 
describe three different routes of lymphatic drainage: an anterior 
route draining the anterior auricle to pre-auricular and superficial 
cervical nodes; an inferior route from the lower auricle to infra-
auricular and deep cervical nodes; and a posterior route draining 
the upper posterior part of the auricle to the post-auricular node(s) 
if  present  and  onto  deep  cervical  nodes.  The  efferent  vessels 
described from the posterior part of the auricle are said to curl 
round  the  anterior  edge  of  the  sternocleidomastoid  muscle  to 
reach the deep cervical nodes.
57, 59 
Despite  what  is  known  about  the  lymphatic  pathways  from 
previous  work,  there  has  been  evidence  from  work  done  on 
sentinel lymph node biopsy in cutaneous melanoma of the head 
and neck to suggest that sentinel nodes do not always appear in 
the locations that would be expected.
80, 81 This evidence questions 
our  understanding  of  the  lymphatic  drainage  pathways  of  the 
head and neck and the principals that both sentinel node biopsy 
and selective node dissection rely upon. In both these operations 
the  assumption  is  made  that  the  flow  of  lymph  from  a  tumour 
follows  a  preset  route  to  a  specific  lymph  node  or  lymph  node 
basin and that this is the route that tumour cells will take as they 
are  shed  of  from  the  primary  tumour  and  travel  to  the  lymph 
nodes. Sentinel lymph node biopsy also relies on the assumption 
that the tracer materials used to identify the lymph nodes will also 
follow the same lymphatic pathway. 
This shows that our understanding of lymphatic drainage of the 
head and neck is incomplete and there is not sufficient information 
available to allow the prediction of the possible locations of lymph 
nodes  which  are  the  drainage  sites  of  specific  tumours.  There 
could  be  unknown  lymphatic  pathways  and  anastamoses  that 
allow drainage of lymph to unexpected locations. Mustafa recently   61 
carried out lymphoscintigraphy of the auricle in healthy subjects 
and  found  that  lymph  nodes  were  found  in  the  expected 
locations.
82 This work does not exclude the possibility that the flow 
of  lymph  can  be  directed  by  the  lymphatic  vessels  in  the  living 
body. 
In  order  to  look  for  lymphatic  vessels  of  the  auricle  a  similar 
method can be used to that used to identify sentinel lymph nodes. 
A dye injected into the skin and sub-dermal tissues of the auricle 
could  be  made  to  flow  along  lymphatic  vessels  towards  lymph 
nodes. A cadaveric model allows dissection and clearing of tissue 
such  that  lymphatic  vessels  can  be  identified  and  should  also 
prevent dynamic re-direction of lymph flow as could occur it the 
living.    62 
 
Figure  8  -  Diagrammatic  representation  of  auricular 
lymphatics  reproduced  from  Kubrick's  Textbook  of 
Lymphology   63 
Materials and Methods 
The  methods  used  were  based  upon  Jameson’s  and  Dobson’s 
methods  for  lymphatic  mapping.
83  Cadavers  for  the  study  were 
provided by the University of Glasgow Anatomy Department. The 
donors  had  died  1-3  days  previous  and  had  been  refrigerated 
after  death.  When  a  cadaver  became  available,  which  was 
deemed suitable for study, a solution of Indian ink diluted at a 
ratio of 1 to 5 with 0.9% saline was made up. This was injected 
intra-dermally  and  subcutaneously  into  the  auricle  through 
multiple injection points sufficient to render the entire external ear 
stained on both anterior and posterior surfaces. (Figure 9) Only 
the skin overlying the cartilage of the ear and the earlobe were 
infiltrated. Once the injection phase was completed, the ear was 
massaged and then in a progressive fashion the tissues overlying 
the skin surrounding the ear, the parotid and neck. 
Once the massaging was complete the body was embalmed using 
a  solution  of  ethanol,  methanol  and  formaldehyde  (Cantabrian 
Fluid,  Vickers  Laboratories).  The  embalming  fluid  was  directed 
either  centrally  through  a  femoral  artery  or  centrally  or  distally 
through a common carotid artery. (Table 7) After embalming the 
body  was  allowed  to  fix  for  between  six  to  eight  weeks  per 
cadaver. Once this process was complete an en-bloc dissection of 
the auricle and lymphatics of the neck and parotid with overlying 
skin was carried out. Superiorly a 2cm margin of skin was taken 
and 5cm posteriorly. This was incised down to peri-osteum. The 
ear canal was detached at the junction between the cartilaginous 
and bony parts. The parotid gland was removed in its entirety. The 
sternocleidomastoid muscle was detached at its upper and lower 
ends  from  bone  and  included  in  the  specimen  along  with  the 
internal jugular vein and carotid artery. The deep muscles of the   64 
neck formed the medial resection margin. No bone was included. 
The aim was to remove the auricle with the lymphatic pathways 
and nodes as one piece intact. 
The dissected specimen was then cleared using a technique based 
upon  the  Spaltenholz  method.  This  consisted  of  stepwise 
dehydration  of  the  specimen  in  several  solutions  of  methylated 
spirits  increasing  in  concentration  from  70%  to  90%  over  two 
weeks, final dehydration in two baths of absolute alcohol (100% 
ethanol) and then clearing in methyl salycilate solution until the 
specimen  became  clear.  (Figure  10)  Once  the  specimens  had 
cleared they were studied in detail and photographed. 
Each specimen was examined to look for lymphatic pathways from 
the auricle and to try to identify the location of the first lymph node 
that these pathways encountered.   65 
 
 
 
Figure 9 - An ear showing staining after injection and 
massage   66 
Table 7 - Summary of Specimen and embalming infiltration details 
Specimen 
Number 
Sex of donor  Age of donor  Side  Site of Embalming 
Fluid Infiltration 
Direction of 
Embalming Fluid 
Infiltration 
One  Female  83  Right  Femoral Artery  Centrally 
Two  Male  68  Left  Contra-lateral 
Common Carotid 
Artery 
Distally 
Three  Male  68  Right  Ipsi-lateral Common 
Carotid Artery 
Distally 
Four  Female  73  Left  Ipsi-lateral Common 
Carotid Artery 
Centrally 
Five  Female  73  Right  Contra-lateral 
Common Carotid 
Artery 
Centrally   67 
Figure 10 - Flow Diagram of Specimen Processing
6-8 weeks 
1-3 days 
Fresh Cadaver Injected with Indian Ink and Embalmed 
Fresh Cadaver Becomes Available and is Refrigerated Pending 
Injection 
Auricle, Parotid & Neck Lymph Glands Dissected En-
Bloc 
Specimen Placed in 70% Methylated Spirits Solution 
70% Methylated Spirits Solution Refreshed 
70% Methylated Spirits Solution Refreshed 
Specimen Transferred to 80% Methylated Spirits 
Solution 
80% Methylated Spirits Solution Refreshed 
1-2 days 
2-3 days 
2-3 days 
2-3 days 
90% Methylated Spirits Solution Refreshed 
Specimen Transferred to 90% Methylated Spirits 
Solution 
2-3 days 
2-3 days 
Specimen Transferred to 100% Ethanol 
100% Ethanol Refreshed 
Specimen Transferred to Methyl Salicylate Solution For Final Clearing 
2-3 days 
2-3 days 
2-3 days   68 
Results 
A total of five specimens were obtained. These represented one 
right ear from an elderly female, a pair of ears from an elderly 
male with a rather short fat neck and a further pair of ears from 
another  elderly  female.  Unfortunately  part  of  the  parotid  gland 
was removed from the first specimen for another demonstration 
which  somewhat  reduced  its  usefulness.  The  Indian  ink  solution 
travelled to a varying degree in each specimen. In the specimens 
where  the  embalming  solution  was  infused  through  the  carotid 
artery on the ipsi-lateral side the ink travelled appreciably further 
than when the contra-lateral carotid or femoral artery was used. In 
addition to the information available from the cleared specimens 
there was additional information from dissecting the specimens. In 
three  of  the  specimens  a  lymphatic  vessel  stained  with  ink  was 
encountered while the specimens were being removed from the 
mastoid bone. The course of this vessel seems to be running from 
supero-lateral  to  infero-medial.  So  close  and  adherent  was  this 
vessel  to  the  periostium  of  the  mastoid  that  it  was  frequently 
damaged  while  the  soft  tissues  of  the  specimen  were  being 
removed from the bone prior to clearing.   69 
Specimen One 
A right ear from an elderly female. (Figures 11 & 12) The upper 
majority of the parotid gland has been removed. This was done by 
dental students to demonstrate the temporo-mandibular joint. The 
dissection they carried out removed the skin as well and hence the 
lower part of the specimen is only loosely attached. This specimen 
demonstrates nodes in several locations which have been stained 
by the ink. Nodes are visible in the following locations: 
•  Deep to the insertion of sternocleidomastoid 
•  Anterior  to  the  internal  jugular  vein  in  the  deep  cervical 
chain and adjacent tail of parotid 
•  Pre-mastoid 
•  Pre-tragal 
It  is  difficult  to  comment  on  the  lymphatic  pathways  in  this 
specimen due the disruption caused by the dental dissection but 
pathways are clearly demonstrated between the nodes in the tail 
of the parotid gland and the deep cervical chain.    70 
 
Figure 11 - Specimen One Lateral View 
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Figure  12  -  Specimen  One  Closeup  Lateral  View 
Showing Stained Nodes And Connecting Lymphatics 
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Specimen Two 
A  left  ear.  (Figures  13  &  14)  This  specimen  shows  staining  of 
lymphatics  and  nodes  in  the  parotid  gland  and  upper  deep 
cervical chain. Nodes are visible at the following locations: 
•  Superficial cervical adjacent to the external jugular vein 
•  Deep cervical around the internal jugular vein 
•  Anterior to sternocleidomastoid in the parotid gland 
The tissue immediately anterior to the auricle has become heavily 
stained with ink preventing identification of any nodes or pathways 
in this area. Lymphatic pathways are evident at three points: 
•  From the anterior auricle to the superficial cervical node 
•  Traversing  the  insertion  of  sternocleidomastoid  to  deep 
cervical nodes 
•  Wrapping  around  the  anterior  border  of 
sternocleidomastoid to deep cervical and parotid nodes 
The  upper  part  of  the  latter  pathway  is  not  visible.  This  is  the 
region where the specimen was scraped off the mastoid bone and 
the pathways were damaged at that time.   73 
 
Figure 13 - Specimen Two Lateral View  
(EJV – External Jugular Vein) 
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Figure 14 - Specimen Two Closeup Medial View 
(SCM – Sternocleidomastoid muscle) 
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Specimen Three 
This is a right ear (Figures 15-17) and shows stained lymph nodes 
at the following locations: 
•  Post-auricular 
•  Pre-mastoid 
•  Deep cervical chain 
•  Parotid gland 
There is evidence of pathways descending from the auricle at four 
places: 
•  To the post auricular node 
•  Traversing the origin of sternocleidomastoid 
•  To the pre-mastoid node 
•  By passing the pre-mastoid node and running to the tail of 
the parotid gland 
This  specimen  also  demonstrates  anastamoses  of  the  lymphatic 
vessels around the post-auricular and pre-mastoid nodes.   76 
 
 
 
Figure 15 - Specimen Three Medial View 
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Figure  16  -  Specimen  Three  Closeup  Medial  View 
Demonstrating  The  Proximity  of  First  Echelon  Nodes  to 
The  Mastoid  Bone  at  The  Insertion  Of  The 
Sternocleidomastoid Muscle 
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Figure 17 - Lymphatic Pathways In Specimen Three 
One – Descending from the auricle to Intra-Parotid nodes 
Two – Descending from the auricle to the anterior mastoid node. 
Lymphatics descending from this were damaged during dissection 
of  the  specimen  and  are  believed  to  connect  with  lymphatics 
stained below this 
Three  -  Descending  from  the  auricle,  traversing  the  origin  of 
sternocleidomastoid to deep cervical nodes 
Four  –  Descending  from  the  Auricle  to  the post-auricular  node. 
Lymphatics  descend  from  this  node  to  the  deep  cervical  nodes
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Figure 18 - 3D Stereogram of Specimen 3 for Parallel Viewing  80 
 
Figure 19 - 3D Stereogram of Specimen 3 for Cross-eyed Viewing   81 
 
Specimen Four 
This is a left ear. (Figures 18 & 19) The ink has travelled less far in 
this  specimen  than  in  others.  The  lymphatic  vessels  leaving  the 
auricle have been stained and seem to be much finer than those 
encountered  in  previous  specimens.  Nodes  are  visible  at  the 
following locations: 
•  Post-auricular 
•  Pre-tragal 
Two lymphatic pathways are visible in this specimen: 
•  From  the  auricle  to  the  post-auricular  node  and  then 
onwards to traverse the insertion of sternocleidomastoid 
•  From  the  auricle  directly  to  traverse  the  insertion  of 
sternocleidomastoid 
   82 
 
Figure 20 - Specimen Four Medial View 
Vessels 
traversing 
SCM 
Pre-tragal 
node 
SUPERIOR 
P 
O 
S 
T 
E 
R 
I 
O 
R 
Post-
auricular 
node   83 
 
Figure 21 - Close up Medial View of Specimen Four 
Lymphatics  can  be  seen  descending  from  the  auricle  and  post-
auricular node to traverse the insertion of sternocleidomastoid. 
Post-
Auricular 
node 
 
Lymphatic 
channels 
SUPERIOR 
P 
O 
S 
T 
E 
R 
I 
O 
R   84 
Specimen Five 
This is a right ear (Figure 20) and demonstrates only one node in 
the  pre-mastoid  area  with  lymphatic  vessels  running  from  the 
auricle to the node and then inferiorly from the node.   85 
 
Figure 22 - Specimen Five Lateral View 
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Discussion 
Summary of Results 
There is clear demonstration that there are at least five potential 
lymphatic  pathways  draining  the  auricle  to  a  first  lymph  node. 
(Figure 21) Working from anterior to posterior: 
1.  A  pre-auricular  pathway  to  pre-auricular  or  superficial 
cervical nodes.  
2.  A pathway from the lower auricle immediately posterior to 
the  external  auditory  canal  to  a  node  lying  immediately 
anterior to the mastoid bone. 
3.  There are vessels bypassing the anterior mastoid node to 
communicate directly with nodes in the lower parotid. 
4.  There  is  a  pathway  from  further  supero-posterior  on  the 
auricle  which  traverses  the  insertion  of  the 
sternocleidomastoid  muscle  to  reach  deep  cervical  nodes 
on the deep surface of the muscle. 
5.  Finally vessels descend from yet further supero-posterior on 
the auricle to a post-auricular node.  
This gives five likely locations for potential sentinel nodes: 
1.  Pre-auricular or superficial cervical 
2.  Lower parotid 
3.  Anterior to the mastoid bone 
4.  Deep to the insertion of sternocleidomastoid inferior to the 
mastoid bone 
5.  Post-auricular 
It is also apparent that there are vessels which form anastamoses 
around post-auricular and mastoid lymph nodes. This means that   87 
embolic tumour cells have a pathway to bypass these nodes. There 
are no anastamoses apparent around the lymph nodes deep to 
sternocleidomastoid  or  in  the  parotid  gland.  This  implies  that 
embolic tumour cells should reach these nodes even if they bypass 
the mastoid or post-auricular nodes. 
In three specimens (1,3&5) there is evidence of a lymph node in a 
position that prior to dissection would have been just anterior to 
the  mastoid  and  inferior  to  the  external  auditory  canal.  The 
lymphatic  channel  that  was  encountered  running  next  to  the 
mastoid bone undoubtedly leads to this node which will be several 
centimetres under the skin. This node is not present in the rest of 
the specimens despite apparent penetration of ink to the required 
distance.  This  could  indicate  that  this  node  is  only  present  in  a 
certain  proportion  of  individuals  and  could  explain  why  in  the 
clinical setting some patients present with metastatic disease which 
has infiltrated the base of skull and adjacent nerves by the time it 
becomes  clinically  palpable,  while  others  present  with  what  are 
possibly more easily detectable metastases of the post-auricular, 
tail  of  parotid  or  cervical  chain  nodes.  Curiously  the  three 
specimens in which this node is present are all right ears.    88 
 
Figure  23  -  Diagrammatic  representation  of  lymphatic 
pathways from the auricle to first echelon lymph nodes   89 
Strengths and Weaknesses of This Study 
This study is limited by the small number of cases that have been 
examined  with  only  five  studies  performed  in  three  cadavers. 
These have all been of Caucasian origin. The distance travelled by 
the Indian ink through the lymphatic system has been variable and 
in several instances has failed to reach beyond the closest nodes. 
Thus there has been no demonstration of variability that may exist 
in  lymphatic  pathways  in  the  general  population  or  in  different 
races. 
There  has  been  no  demonstration  of  dynamic  flow  and  no 
comment can be made about the direction that flow of lymphatic 
fluid  and  embolic  tumour  cells  takes  in  the  living.  The 
demonstration  of  anastamotic  pathways  around  lymph  nodes 
could explain why some sentinel lymph nodes have been found in 
previous work to be in abnormal locations but it is not possible to 
know from this work what influences the direction and volume of 
flow in these. In the living such flow may be constrained by local 
vessel  tone,  valves  or  other  mechanisms  which  become 
unapparent  post-mortem.  Conversely  there  may  also  exist 
lymphatic vessels which are kept open during life but collapse after 
death and have not been demonstrated here. 
The lymphatic pathways that have been demonstrated in this study 
have appeared to come from certain parts of the auricle but no 
conclusions  can  be  drawn  about  what  part  of  the  auricle  they 
drain.  This  study  has  looked  at  the  auricle  as  a  whole  and 
inferences about lymphatic drainage of any particular part of the 
auricle cannot be made upon the basis of this work. 
Despite these weaknesses the study has effectively demonstrated 
several  lymphatic  pathways  and  identified  nodal  locations.  The 
technique used in this study seems to have worked best when the   90 
embalming  fluid  was  infiltrated  distally  through  the  ipsilateral 
common carotid artery. This is conceivably due to the fact that it 
has caused some additional flow in the lymphatic vessels during 
the  embalming  process.  The  skin  of  the  cadaver  perceivably 
changes  colour  as  the  embalming  fluid  is  infiltrated  and  is 
therefore  likely  to  increase  pressure  inside  the  tissues  and  then 
forcing fluid through lymphatics. 
Even with this apparent success of the technique it is impossible to 
know how effective this technique is in penetrating all the available 
lymphatics. Given that Indian ink solution is made up of a range 
of particle sizes in solution it may be that only certain lymphatic 
vessels permit entry of these particles and the massaging used to 
move the ink after injection may favour vessels of larger calibre.   91 
Comparison With The Work of Others 
This work confirms the described existing pathways of lymphatic 
drainage of the auricle to post-auricular, mastoid, pre-auricular, 
parotid, superficial and deep cervical lymph nodes.
57,  59 However 
only one specimen demonstrated any flow to superficial cervical 
lymph nodes, which are commonly mentioned in textbooks.  
The  presence  of  this  lymphatic  channel  crossing  through  the 
insertion  of  the  sternocleidomastoid  is  absent  from  modern 
textbooks although its presence has been noted before by Rouviere 
in  his  early  work  on  lymphatics.
58  This  pathway  has  serious 
implications for the operative technique used and knowledge of its 
presence is paramount for head and neck surgeons. 
The use of Indian ink solution for the staining of lymphatics has 
previously been discouraged by authors such as Turner-Warwick 
who  felt  that  they  were  not  diffusible  enough  to  provide  good 
staining of lymphatics.
84 This study has however demonstrated that 
they  can  be  carried  by  lymphatics  and  provide  excellent 
persistence after clearing.   92 
Meaning of This Study 
The  findings  of  this  study  are  useful  in  clinical  practice  in  two 
areas:  Firstly  with  reference  to  sentinel  lymph  node  biopsy  the 
potential  five  locations  of  sentinel  nodes  con  be  used  with pre-
operative lymphoscintigraphy to plan incision sites and dissection 
strategy.  Knowledge  of  the  lymphatic  pathways  is  helpful  when 
performing  a  sentinel  node  biopsy  with  blue  dye  to  guide 
dissection. In particular knowing a pathway crosses the insertion of 
sternocleidomastoid means that the operator can look for sentinel 
nodes deep to the muscle rather than dissecting the muscle off the 
mastoid in order to follow the blue stained vessels. The dissection 
of  blue  stained  lymphatics  is  a  time  consuming  and  delicate 
procedure  and  knowledge  of  where they  are  likely  to  terminate 
allows directed dissection of lymph nodes which can be localised 
with a gamma probe.  
It is also important to be aware of the presence of anastamotic 
pathways around the most proximal nodes that drain the auricle. 
These nodes could easily be the first identified at a sentinel node 
procedure and the temptation to remove only these node(s) could 
lead to a false negative sentinel node biopsy. 
Secondly  with  reference  to  lymphadenectomy  procedures  it  is 
important when trying to surgically remove any lymphatic deposits 
of  tumour  to  perform  an  oncologically  sound  procedure.  This 
means complete removal of the efferent lymphatic pathways and 
lymph nodes. In order to achieve this it will be necessary to dissect 
in a sub-peri-osteal plane on the mastoid bone and remove the 
insertion of sternocleidomastoid.    93 
Unanswered Questions and Future Research 
Further  work  would  be  required  to  confirm  the  frequency  with 
which these pathways and nodal locations occur in the general 
population and between different racial groups. It may be of value 
to try the technique with different dyes such as Pontamine Sky Blue 
or  Direct  Sky  Blue  which  are  believed  to  be  more  easily 
transported in lymphatics and less persistent at the injection site.
84  
It  would  also  be  of  great  value  to  try  to  demonstrate  these 
pathways in living tissue. This could be done at the time of sentinel 
node biopsy for auricular malignancies and would answer some 
of  the  questions  about  flow  in  these  pathways.  It  may  also  be 
possible with a sufficient number of positive sentinel node biopsies 
to determine whether or not the anastamotic pathways around the 
post-auricular  and  mastoid  nodes  allow  the  passage  of  tumour 
cells to lower nodes – so called ‘skip metastases’. 
   94 
Conclusions 
In order to confidently remove the likely potential locations of sub-
clinical  metastatic  disease  in  the  lymph  node  basins  any 
lymphadenectomy  must  include  the  pre-auricular  nodes,  post-
auricular  nodes,  superficial  parotid  gland,  upper  deep  cervical 
chain and special attention must be given to resecting the tissue 
between the mastoid and the mandible just inferior to the external 
auditory  canal  with  at  minimum  sub-periosteal  resection  and 
possibly removal of the mastoid process. In addition the upper end 
of the sternocleidomastoid muscle must be sacrificed. In line with 
other selective neck dissection it would be standard to also remove 
the  next  level  down  the  lymphatic  chain  and  this  would  mean 
including levels two and three. In a clinically node negative patient 
this  should  provide  adequate  staging  and  if  small  metastatic 
deposits are found on pathological examination they would likely 
be confined to the upper part of the specimen and therefore not 
likely to require further surgery. 
When performing sentinel node biopsy the sentinel nodes may be 
found at any one of these locations but it must not be assumed 
that the node(s) closest to the auricle are the first nodes to which 
tumour may travel due to the presence of anastamotic pathways 
around these nodes.   95 
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Summary 
Introduction 
Sentinel lymph node biopsy is an emerging technique which has 
gained  much  favour  in  the  treatment  of  malignancies  such  as 
breast cancer and melanoma because it allows accurate staging 
of  the  regional  lymph  nodes  with  minimum  morbidity.  Early 
accurate  staging  of  the  regional  lymph  nodes  in  auricular 
squamous cell carcinoma is desirable because of the difficulty in 
treating established metastases. 
Materials and Methods 
28  cases  of  auricular  squamous  cell  carcinoma  in  27  patients 
were recruited for sentinel lymph node biopsy. 
Results 
No  patient  was  found  to  have  evidence  of  metastases  in  the 
regional  lymph  nodes.  One  patient  proved  to  have  non-viable 
tumour cells in one node. There was a high complication rate of 
the  sentinel  node  biopsy  procedure.  No  patient  has  developed 
evidence of regional metastases in the follow up period. 
Conclusions 
Sentinel  lymph  node  biopsy  for  these  tumours  seems  to  be 
technically  possible  but  care  has  to  be  taken  to  minimise 
complications.  The  results  do  not  support  the  routine  use  of 
sentinel lymph node biopsy in auricular squamous cell carcinoma. 
The  lymphatic  drainage  patterns  discovered  with  this  technique 
have  significant  implications  for  performing neck  dissections  for 
spread of these tumours.   97 
Introduction 
Sentinel  lymph  node biopsy  is  an  emerging  surgical  tool  in  the 
management  of  malignancies  that  develop  lymph  node 
metastases. The technique was born out of a need for accurate 
staging of the regional lymph node basins to allow treatment to be 
directed  only  where  and  when  it  is  needed.  Prior  to  the 
development of this technique there were two previous accepted 
methods for the management of the local lymph node basins in 
patients  with  no  clinical  evidence  of  lymphatic  metastases;  the 
‘wait  and  see’  policy  where  regular  clinical  assessment  or 
radiological imaging was used to direct therapy to the lymph node 
basins  and  the  prophylactic  treatment  policy  either  by  elective 
lymphadenectomy, radiotherapy, chemotherapy or a combination 
of these. Electively removing the lymph nodes had the combined 
benefit  of  providing  histo-pathological  staging  of  disease  that 
could direct other therapy or provide prognostic information for 
the patient. 
Historically patients were allocated to one management policy or 
another based upon a cost benefit balance between the risks and 
morbidity associated with the treatment and the potential for the 
primary  tumour  to  develop  metastases  based  upon  what  was 
known about the primary tumour staging. There has been no cost 
benefit  analysis  of  this  kind  done  specifically  for  auricular 
squamous  cell  carcinoma  but  malignancy  of  the  upper  aero-
digestive tract drains to similar lymph node basins and therefore 
morbidity and risks of elective lymphadenectomy are similar. For 
malignancies at this site a 15 to 20% risk of development of lymph 
node metastases is  accepted as sufficient to direct elective neck 
dissection.
72, 85, 86    98 
Auricular  squamous  cell  carcinoma  has  a  metastatic  rate  of 
around  11%  and  there  is  insufficient  information  available  to 
stratify the risks  of specific tumours. 
1-3 This  means that elective 
lymphadenectomy  or  other  treatment  to  the  lymph  node  basins 
cannot be determined. 
Sentinel  lymph  node  biopsy  is  a  less  invasive  technique  than  a 
formal  lymph  node  dissection  and  is  believed  to  have  less 
morbidity. Therefore it is applicable in tumours with a reduced risk 
of  development  of  metastases  when  compared  to  elective  neck 
dissection.
87  
The Sentinel Node Concept 
The  technique  of  sentinel  lymph  node  biopsy  relies  upon  the 
assumption that lymphatic fluid and tumour cells from the region 
of the body where the tumour lies drains consistently to one or 
more  lymph  nodes.  The  first  lymph  node(s)  encountered  by  the 
efferent  lymphatics  from  the  tumour  site  are  termed  the  first 
echelon nodes and represent the most likely location for embolic 
tumour  cells  to  become  seeded  once  they  leave  the  primary 
tumour. Since lymph nodes lie in chains and drain from one to 
another  before  eventually  draining  towards  a  central  collecting 
system  and  into  the  venous  circulation,  there  are  also  second 
echelon  nodes,  third  and  so  on.  The  early  sentinel  node  work 
relied upon knowing the anatomical location of the first echelon 
node and removing it for histological examination. 
The technique used now is a dynamic method for locating these 
first  echelon  nodes  which  allows  for  variations  in  lymphatic 
drainage patterns between individuals and can be applied to any 
tumour site for which there may not be information about the first 
location  of  metastases.  Two  types  of  tracer  material  can  be 
injected around the edge of a tumour, which help to locate the   99 
sentinel  nodes.  Firstly  radioactively  labelled  colloid  can  be 
injected. This is taken up by efferent lymphatics and travels to the 
lymph nodes where it becomes bound and hence concentrates the 
radioactivity. This allows dynamic or static images to be taken with 
a gamma camera and a gamma probe to be used to locate the 
nodes. Secondly coloured dyes such as patent blue are similarly 
injected and taken up in lymphatic vessels. These act as a visual 
guide when dissecting tissue and allow easy identification of target 
nodes. 
History of Sentinel Node Biopsy 
The  term  was  originally  introduced  for  a  surgical  technique  for 
harvesting lymph nodes at specific locations which were known to 
be  the  first  location  for  lymphatic  metastases  for  specific 
malignancies.
88 Gould is credited with the first description of this 
for tumours of the parotid gland where frozen section examination 
of  a node that lay at the junction of the anterior and posterior 
facial  vein  would  be  used  to  decide  upon  the  need  for  a  neck 
dissection  or  not.  This  prompted  other  such  as  Cabañas  and 
Chiappa who studied the lymphatics of the penis and the testicle 
respectively  to  find  sentinel  node  locations  for  tumours  at  these 
sites.
89, 90 
The use of dynamic location of nodes was pioneered by Morton, 
for melanoma, who injected gold to locate lymph nodes and later 
added  blue  dye.
91  Guiliano  introduced  the  use  of  blue  dye  for 
breast cancer but the use of these dyes in tracing lymphatics can 
be traced much further back to earlier anatomical work such as 
that of Turner-Warwick.
84, 92 
Reintgen  and  Kapteijn  published  work  to  show  that  metastatic 
spread followed a stepwise progression starting in the first echelon   100 
node(s) and this validated sentinel lymph node biopsy as a staging 
tool in melanoma and breast cancer.
93, 94 
Recently our own unit has pioneered the use of this technique in 
malignancies of the upper aero-digestive tract and so far it has 
proved to be a reliable and accurate method of staging the lymph 
nodes.
75, 95 
The Current Use of Sentinel Lymph Node Biopsy 
Despite  the  validation  of  the  technique  its  use  in  melanoma 
remains  controversial.  It  is  the  most  useful  prognostic  indicator 
and recently there has been some suggestion that patients who 
have elective lymph node dissections based upon sentinel lymph 
node biopsy may have some survival advantage over a wait and 
see  policy  but  this  is  far  from  established  fact.
96-99  Certainly  in 
centres where elective lymph node dissections were performed for 
melanoma it has reduced the morbidity. The presence of lymph 
node metastases is an indicator of systemic disease and warrants 
therapeutic lymph node dissection.
97 More work is being carried 
out  at  present  to  determine  if  there  is  a  survival  advantage  for 
those patients with micro-metastases in sentinel lymph nodes. This 
may be a group of patients whose only metastatic spread is to the 
regional lymph nodes and not associated with distant metastases. 
Many clinicians will still offer patients sentinel lymph node biopsy 
because of the prognostic information which may be of value to 
the patient and current SIGN guidelines recommend that it should 
be  considered  in  all  patients.
100  In  some  cases  it  can  allow  a 
patient to be entered into a clinical trial because of upstaging of 
disease.   101 
Potential Usefulness In Auricular SCC 
Lymph node metastases from auricular squamous cell carcinoma 
are associated with specific problems due to their proximity to the 
skull base and associated nerves and vessels. Resection of these 
lymph  node  metastases  once  established  is  associated  with 
significant morbidity and it is often failure to control loco-regional 
disease that leads to death.
2, 3, 45 Accurate and early staging of the 
local  lymph  nodes  in  auricular  squamous  cell  carcinoma  is 
beneficial as usually loco-regional control is curative. In auricular 
squamous cell carcinoma distant metastases are exceedingly rare 
with only one case reported.
45  
It  would  seem  therefore  an  inviting  disease  for  sentinel  lymph 
node  biopsy  but  there  are  several  features  of  the  auricle  that 
require special consideration before employing this technique. The 
auricle is known to drain to three different lymph node basins – 
the  parotid,  post-auricular  and  deep  cervical.
58,  101  There  are 
several different pathways for a rather small area of skin and this 
is different to the rest of the skin of the body. It is likely that the 
lymphatic drainage territories overlap and even if they did not a 
tumour would not need to grow to a particularly large size to affect 
two or even three different drainage pathways. This possibility for 
tumour  spread  may  explain  to  some  degree  why  auricular 
squamous  cell  carcinoma  has  a  metastatic  rate  of  11%  when 
compared  to  the  rate  of  0.5-2%  for  the  skin  of  the  body  as  a 
whole.
9,  13  However  this  choice  of  pathways  may  lead  to 
discrepancies with sentinel node biopsy as it assumes that they are 
all  patent  at  all  times  –  there  is  no  direct  evidence  for  this.  In 
addition  the  proximity  of  the  primary  tumour  to  the  expected 
location of lymph nodes will make pre-operative imaging with a 
gamma camera difficult. This has in the past lead to a failure of 
the technique in accurately staging disease in the neck.
75   102 
 
Study Design 
Canniesburn  Plastic  Surgery  Unit  has  in  recent  years  excised 
approximately 50 auricular squamous cell carcinomas per annum. 
This figure was obtained by reviewing pathology reports, copies of 
which are collected centrally. The time allocated to this project was 
two years giving a maximum of 100 cases. Patients with auricular 
squamous cell carcinoma are known to be elderly and often have 
co-morbidities.  Many  of  these  co-morbidities  include  conditions 
that would significantly increase the risk of a general anaesthetic 
to the patient and therefore would exclude them from any sentinel 
node trial.
102 It was estimated that approximately 40 patients could 
be recruited over two years. 
One  possible  study  design  was  to  randomise  patients  into  two 
groups  with  one  group  of  patients  having  SNB  and  the  other 
group acting as controls. This would allow the comparison of SNB 
and targeted therapy to affected lymph node basins with clinical 
observation  and  subsequent  treatment  of  affected  lymph  node 
basins. The end-point of such a trial would be evidence of lymph 
node recurrence in controls or sentinel node negative patients. A 
simple power calculation shows that even if sentinel lymph node 
biopsy detected all metastatic spread, i.e. the recurrence rate in 
that group was nil, then 67 patients would be required in each 
group for a power of 0.80 and a probability of 0.05.   103 
Power Calculation 
p1 = 0.11 – 11% expected recurrence in control group 
p2 = 0 – 0% expected recurrence in sentinel node group 
! = 0.05  
power = 0.80 
group size = 67 in each group 
A  reverse  power  calculation  shows  that  if  40  potential  patients 
were recruited and split in to 2 groups of 20 then the power of the 
study would be 0.27 which is too low to provide any meaningful 
results. 
For  these  reasons  a  non-randomised  observational  study  was 
designed which would allow the evaluation of sentinel lymph node 
biopsy  as  a  staging  tool  for  the  lymph  node  basins  potentially 
involved  in  auricular  squamous  cell  carcinoma.  The  histo-
pathological processing that sentinel lymph nodes are subjected to 
is believed to make it highly unlikely that any metastatic spread in 
missed. This means that patients could act as their own controls 
with evidence of lymphatic spread outwith the sentinel nodes taken 
to  be  a  failure  of  the  technique.  It  is  possible  to  perform 
completion  lymphadenectomy  procedures  after  sentinel  node 
harvesting as is done for melanoma of the head and neck.
97 For 
auricular  carcinoma  this  would  require  a  neck  dissection, 
superficial parotidectomy and post-auricular node resection. This 
is not the current standard of care and would subject the majority 
of  patients  in  the  study  (expected  89%)  to  lengthy  unnecessary 
procedures  with  associated  significant  morbidity.  Furthermore  in 
order  to  be  sure  that  none  of  the  non-sentinel  nodes  in  the 
specimens  contained  tumour  they  would  all  have  to  be 
meticulously  dissected  out  and  subjected  to  the  same  histo-
pathological analysis as the sentinel nodes.    104 
The alternative was to perform sentinel lymph node biopsy without 
completion  lymphadenectomy  and  then  monitor  the  patient  for 
clinical signs of recurrence. Previous reported series have shown 
that 85% of metastases declared within 12 months of the initial 
tumour  and  only  a  few  isolated  cases  have  occurred  after  24 
months.
3, 36, 38, 45, 65 This design has the advantage that patients are 
not  subject  to  additional  unnecessary  surgery  and  treatment  is 
similar to current practice.   105 
Materials and Methods 
Patient Recruitment and Enrolment 
Ethical approval was obtained for the study from Glasgow Royal 
Infirmary’s local ethics committee. Patients were recruited from a 
weekly clinic held every Monday morning in outpatient department 
of Canniesburn Plastic Surgery Unit. All plastic surgery consultants 
and registrars were written to and personally canvassed to refer all 
new cases of auricular squamous cell carcinoma to this clinic. All 
dermatology consultants in Glasgow and surrounding area were 
also written to request referral of appropriate patients. 
Patients were included in the trial if they had histological evidence 
of auricular squamous cell carcinoma. (Table 8) This could be by 
incisional, punch or excision biopsy. Patients were excluded if they 
were deemed to be at risk from the procedure due to the nature of 
the surgery and anaesthetic involved. For the purposes of the study 
this was defined as an American Society of Anaesthesia Grade 3 
or higher. Pregnant patients were to be excluded on the grounds 
that radioactivity could damage a foetus and under 18 year olds 
were excluded on ethical grounds. 
   106 
Table 8 - Inclusion and exclusion criteria 
Inclusion Criteria  Biopsy proven Auricular SCC 
Exclusion criteria  ASA Grade 3 or over 
  Clinical  Evidence  of  Lymph 
Node Metastases 
  Age <18 years 
  Pregnancy 
(ASA- American Society of Anesthesiologists)   107 
Pre-operative Lymphoscintigraphy 
The  radio-colloid  (Tc-99  labelled  Nanocol)  was  injected  around 
the  edge  and  deep  margin  of  the  tumour  within  the  24  hours 
preceding surgery. Local anaesthesia was not used as it was felt 
this may affect blood flow and hence lymph flow. The dose used 
was between 20-30mBq in line with ARSAC guidelines in a volume 
of 0.2 to -0.3 ml. The patient was imaged with a gamma camera 
15 minutes after injection. A cobalt 57 flood was used to provide 
an  outline  of  the  patient’s  head  in  order  to  ease  with  image 
orientation and node localisation at the time of surgery. Lateral 
images were obtained with the primary injection site obscured with 
a lead mask. (Figure 22) In cases where it was felt possible that 
the lead mask may have been overlying the possible site of target 
nodes,  a  second  image  was  taken  without  the  lead  mask  and 
software masking used. Anterior images were obtained in the first 
few  cases  but  were  thereafter  abandoned,  as  they  provided  no 
useful  information.  Images  were  printed  and  used  to  guide 
surgery. A permanent marker was used to place a mark over the 
target node guided by a radioactive tipped pen.   108 
 
Figure  24  -  A  typical  Pre-operative  Lymphoscintigram 
Showing    Superiorly  an  Image  with  a  lead  mask  over 
the  Primary  Tumour  and  Inferiorly  an  Image  Without. 
Nodes are visible Pre and Post-Auricular and in the tail 
of the parotid gland.   109 
Operative Technique 
Within the next 24hours the patient’s operation was performed. 
This was usually done under general anaesthesia although in two 
cases regional anaesthesia and sedation was used. After induction 
of anaesthesia blue dye (Patente Blue) was injected in a similar 
fashion to the radio-colloid around the edges of the tumour. The 
position of the radioactive nodes was then checked with a hand 
held  collimated  gamma  probe  (Neoprobe)  to  ensure  the  skin 
markings were accurate after the positioning of the patient. The 
probe  was  then  systematically  swept  at  a  slow  speed  over  the 
parotid gland, post-auricular region and upper neck to look for 
possible sites of radioactivity that had been missed or obscured by 
the primary tumour site during the imaging phase. Any additional 
areas  of  radioactivity  were  marked.  A  skin  incision  was  then 
designed to give access to the target areas in such a fashion that it 
could be incorporated into any incisions made for further surgery 
for  completion  lymphadenectomy.  Dissection  to  identify  nodes 
guided by blue stained lymphatics and the hand held probe then 
followed  with  careful  attention  to  the  preservation  of  nerves 
particularly the facial and greater auricular. Nodes were labelled 
as hot or cold depending on whether the level of radioactivity in 
them  was  above  background  and  blue  or  pale  if  there  was 
evidence of blue staining or not. Once all target nodes had been 
removed  and  the  wound  closed  then  the  primary  tumour  was 
excised. Nodes were identified by location and this was subdivided 
into  parotid,  superficial  cervical,  deep  cervical,  mastoid  (nodes 
immediately anterior to the mastoid bone but not in the parotid), 
post-auricular, pre-auricular (not in parotid).   110 
Histo-pathological Processing 
The primary tumour specimens were processes according to our 
pathology  department’s  standard  protocol  with  blocks  taken  to 
study  the  morphology  of  the  tumour  and  assess  margins.  The 
sentinel  lymph  nodes  were  analysed  according  to  a  protocol, 
which  was  set  up  previously  in  our  unit  for  oral  and  oro-
pharyngeal  squamous  cell  carcinoma.  It  is  known  from  this 
previous sentinel node work that the use of additional histology 
such  as  step  serial  sectioning  and  immunohistochemical  stains 
increases  the  detection  rate  of  metastases  by  up  to  20%  when 
compared  with  conventional  histological  examination.
95,  103 
Sentinel nodes were initially inspected grossly and measurements 
taken,  they  were  then  bisected  longitudinally  through  the  hilum 
and initial sections taken from the surface of each half and stained 
with  haematoxylin  and  eosin  staining  (H&E).  If  no  tumour  was 
found at this stage the remaining tissue was divided at 150 micron 
intervals  working  outwards  from  the  initial  bisection  and  in  the 
same plane. Two sections were then taken from each side of this 
division giving four sections from every 150 micron interval. These 
sections  were  numbered  1  to  4  from  the  centre  of  the  node 
outwards. Section numbered 2 was then  stained with H&E and 
examined.  If  no  tumour  was  evident  then  sections  numbered  3 
were stained with a cytokeratin 8 and 18 marker (AE1/AE3, Mouse 
Anti-Human Cytokeratin Clone, Dakocytomation). These sections 
were then examined. Sections 1 and 4 were kept in reserve in case 
further examination was required because of technical failure or 
diagnostic dubiety.   111 
Post-operative Management 
No specific treatment protocol was defined for those patients who 
showed  evidence  of  tumour  within  the  lymph  nodes.  There  are 
several  treatment  options  and  the  decision  to  use  any  or  all  of 
these  would  be  based  upon  the  level  of  disease  present  in  the 
sentinel nodes, the co-morbidities and wishes of the patient. Our 
unit  presents  weekly  at  a  multidisciplinary  head  &  neck  cancer 
meeting  and  it  was  proposed  that  any  patients  with  positive 
sentinel nodes would be discussed at this venue to plan treatment 
options. 
Patients  without  evidence  of  tumour  in  sentinel  nodes  would be 
followed up in clinics every three months for the first two years and 
six  monthly  thereafter  till  five  years  had  passed  since  they  had 
active disease. A clinical examination of lymph node basins would 
be  carried  out  at  each  clinic  visit  and  any  suspicion  of  disease 
would  be  investigated  by  ultrasound  scan  with  fine  needle 
aspiration cytology where appropriate.   112 
Results 
A total of 29 instances of auricular squamous cell carcinoma were 
diagnosed by biopsy in 28 patients who consented to be enrolled 
in  the  study.  One  case  was  bilateral  and  a  simultaneous 
procedure  was  carried  out  on  both  sides.  One  case  was 
diagnosed  as  SCC  on  the  basis  of  an  incisional  biopsy  and 
enrolled in the study. However upon formal excision of the lesion 
and sentinel node biopsy the diagnosis was changed to basal cell 
carcinoma  with  areas  of  squamous  differentiation.  This  reduced 
the  total  number  of  definitive  cases  of  auricular  squamous  cell 
carcinoma to 28 in 27 patients. 16 of these were on the right and 
12 on the left. 
Of the 28, 8 (29%) had their tumour diagnosed by excision biopsy 
prior  to  referral  for  the  study  the  remainder  had  an  incisional 
biopsy to confirm diagnosis.  
The commonest location  of primary tumours was on the helical 
rim  that  accounted  for  22  tumours  (78.6%),  followed  by  the 
posterior surface with 4 tumours (14.3%) and tragus and anti-helix 
each accounted for one case (3.6%). (Figure 23)    113 
 
Figure 25 - Location of Primary Tumours 
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Histo-pathological Findings 
Primary Tumours 
The primary tumours varied in their size and histological features 
(Table  9)  both  of  which  have  been  suggested  as  possible 
indicators  of  increased  metastatic  potential.  (Table  10)  The 
maximum diameter ranged from 5 to 36mm with a mean of 16.3. 
Depth of invasion ranged from 1 to 10mm with a mean of 3.7.  
Four  tumours  were  felt  to  be  well  differentiated,  13  moderately 
well  differentiated  and  11  poorly  differentiated.  Six  had  non-
cohesive invasive fronts and four displayed evidence of peri-neural 
invasion. No tumours were found to have evidence of vascular or 
lymphatic channel invasion. All tumours were completely excised 
at peripheral and deep excision margins. At no point in any of the 
examined margins was the completeness of excision thought to be 
in question. 
Sentinel Lymph Nodes 
One patient had two cytokeratin positive cells at the periphery of 
one lymph node located in the tail of the parotid gland. (Figure 
24) There were no nuclei visible in these cells. (Figure 25) These 
were  interpreted  to  be  non-viable  tumour  cells.  No  further 
treatment was given to this patient. This patient’s primary tumour 
was a 5mm thick poorly differentiated SCC with evidence of peri-
neural invasion on the left helix. 
No  patients  had  evidence  of  viable  metastatic  tumour  cells  in 
sentinel lymph nodes after full examination with the sentinel node 
protocol.  This  gives  a  metastatic  rate  of  0%  in  this  series  (95% 
confidence interval 0-12%).   115 
Table 9 - Histo-pathological features of primary tumours 
Case Number 
Maximum 
diameter 
Depth of 
invasion 
Degree of 
Histological 
Differentiation  Invasive front  Structure invasion 
1  20  5  poor  Cohesive  None 
2  14  3  moderate  Cohesive  None 
3  12  1.8  well  Cohesive  None 
4  14  3  poor  Non-cohesive  Peri-neural 
5  13  3  moderate  Cohesive  None 
6  13  4  moderate  Cohesive  None 
7  12  2  moderate  Cohesive  None 
8  12  1.8  well  Cohesive  None 
9  15  1  moderate  Cohesive  None 
10  15  2  moderate  Cohesive  Peri-neural 
11  36  6  poor  Cohesive  None 
12  13  2.5  poor  Non-cohesive  None 
13  25  4  moderate  Cohesive  Peri-neural 
14  5  5  poor  Non-cohesive  Peri-neural 
15  18  4.4  poor  Cohesive  None 
16  22  4  moderate  Cohesive  None 
17  14  2.5  moderate  Cohesive  None 
18  20  5  poor  Non-cohesive  None 
19  15  5  moderate  Cohesive  None   116 
20  10  2  moderate  Cohesive  None 
21  22  3  well  Cohesive  None 
22  12  2  moderate  Cohesive  None 
23  25  3  well  Cohesive  None 
24  15  6.5  poor  Non-cohesive  None 
25  10  4  poor  Cohesive  None 
26  20  10  poor  Non-cohesive  None 
27  14  4  moderate  Cohesive  None 
28  20  3  poor  Cohesive  None 
Maximum  36  10       
Average  16.3  3.7       
Minimum  5  1       
 
   117 
Figure 26 – Cytokeratin stained cells at 40x Magnification 
   118 
Figure 27 – Adjacent section stained with haematoxylin & eosin 40x 
Cytokeratin 
positive  cells 
stained  in 
previous  slide 
with no nuclei 
visible   119 
Table 10 – Number of Tumours with Potentially Adverse 
Prognostic Indicators 
Non-cohesive invasive front  6 (21%) 
Poorly Differentiated  10 (36%) 
Peri-neural Invasion  4 (14%) 
Depth > 4mm  8 (29%) 
Diameter > 20mm  5 (18%)   120 
Complications of Treatment 
Infection was a commonly encountered complication. Two patients 
developed infection at the site of resection of the primary tumour. 
In one of these cases the site of sentinel lymph node biopsy also 
became infected. Isolated infection of the lymph node biopsy site 
occurred in two patients. Only the case with infection at both sites 
required re-admission and use of intra-venous anti-microbials to 
treat  the  infection.  This  was  an  infection  due  to  a  methicillin 
resistant staphylococcus aureus. The defect of the primary tumour 
was covered by a full thickness skin graft which was lost as a result 
of  infection.  The  patient  opted  to  allow  the  wound  to  heal  by 
secondary intention rather than re-grafting after the infection had 
been treated. All other infections were treated as outpatients with 
oral antibiotics.  
Four of the patients with infection occurred relatively early in the 
series including two of the sentinel node wound infections. These 
patients had not been given prophylactic antibiotics and the neck 
wounds  had  been  noted  to  be  slightly  swollen  of  the  first  post-
operative  day.  This  resulted  in  a  change  of  policy  and  all 
subsequent  patients  were  given  prophylactic  intravenous 
antibiotics  (co-amoxiclav  1.2G)  at  the  start  of  the  procedure. 
Additionally a small suction drain was placed in the sentinel node 
wound.  These  drains  were  invariably  removed  the  morning 
following surgery with less than 20ml of fluid in them. Only one of 
the infections occurred after this policy was instituted. 
One patient  who  had  a  wedge resection  carried  out  for  helical 
tumour  developed  a  wound  dehiscence.  There  was  no  obvious 
infection of the wound and the patient elected not to have further 
surgery to correct the resultant deformity.   121 
One patient developed a temporary parasthesia in the distribution 
of the Greater Auricular nerve. This resolved gradually over the 
course of 4 months. This nerve was frequently encountered during 
surgery and often had to be retracted to allow access to target 
nodes located within the parotid gland.  
Another  patient  complained  of  a  firm  3cm  diameter  sub-
cutaneous mass overlying the vastus medialus muscle on the thigh 
4  months  after  the  sentinel  node  biopsy.  This  had  apparently 
appeared  spontaneously  at  least  3  months  after  the  procedure. 
This was treated by excision biopsy and histopathology reported 
an area of fat necrosis without obvious cause. No link has been 
established between this and the sentinel node biopsy procedure 
nor has any other cause such as precedent trauma been identified. 
One patient developed a sore painful and inflamed scar over the 
antihelix following wedge resection of a helical tumour. This was 
diagnosed  clinically  as  chondrodermatitis  nodularis  helicis.  This 
diagnosis was confirmed by excision biopsy of the scar at which 
time the shape of the cartilage of the antihelix was refashioned. 
One  patient  who  had  a  total  amputation  of  the  auricle  as  a 
treatment  for  a  primary  tumour  which  involved  the  external 
auditory  canal  developed  meatal  stenosis  which  was  treated  by 
dilation.  
This gives a total of 10 patients (35.7%) with some complication of 
treatment. Four of these (14.3%) are directly related to the sentinel 
node procedure. These were three neck wound infections and one 
temporary parasthesia of the greater auricular nerve. (Table 11)   122 
 
Table 11 - Complications of Treatment 
Complication  Number of Patients Affected 
Wound Infection 
   Of auricle 
   Of neck 
5 (17.9%) 
3 (10.7%) 
3 (10.7%) 
Wound dehiscence  1 (3.6%) 
Greater Auricular Nerve Palsy  1 (3.6%) 
Chondro-deratitis  1 (3.6%) 
Fat necrosis in thigh  1 (3.6%) 
Meatal stenosis  1 (3.6%) 
Total  10 (35.7%) 
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Location  of  Sentinel  Nodes  and  Lymphatic 
Pathways 
The commonest location of sentinel nodes was in the tail of the 
parotid gland with over half of the total number of nodes being 
found  at  this  location.  (Figure  26  &  Table  12)  Six  nodes  were 
harvested  in  direct  contact  with  the  periostium  of  the  mastoid 
bone.  Three  of  these  lay  anterior  to  the  mastoid,  two  directly 
inferior and one on the lateral surface deep to the fascia at the 
superior end of the insertion of sternocleidomastoid (SCM). These 
nodes  lay  on  two  lymphatic  pathways  which  were  frequently 
encountered  during  the  procedure.  The  anterior  of  theses 
pathways ran subcutaneously in the post–auricular sulcus before 
turning  medially  to  run  along  the  mastoid  just  inferior  to  the 
external auditory canal then turned inferior still running along the 
mastoid  before  then  descending  towards  the  tail  of  the  parotid 
gland.  Nodes  were  encountered  at  various  points  along  this 
pathway as it was in close contact with the mastoid, though never 
more than one node in any patient.  
Posterior to this lay a second pathway which sometimes started at 
a post-auricular node, superior to the upper limit of SCM, then ran 
directly under the fascia of the SCM insertion and lying directly on 
the periosteum descended infero-medially across the insertion of 
the  muscle  to  the  upper  end  of  the  deep  cervical  chain.  Again 
nodes  were  encountered  at  various  points  along  this  tract  one 
under the SCM fascia and two deep to the SCM just inferior to the 
mastoid bone. Access to these last two nodes required SCM to be 
split  along  the  line  of  its  fibres,  as  it  was  not  possible  to  gain 
access to this region from anterior or posterior by retracting the 
muscle.   124 
The third commonly encountered pathway ran from the anterior 
auricle around the level of the tragus and drained to pre-auricular 
and superficial cervical lymph nodes.   125 
Figure 28 - Locations of Sentinel Nodes 
 
Post-auricular 6% 
Pre-mastoid 6.8% 
Deep cervical 12.8% 
Pre-auricular 7.7% 
Superficial cervical 1.7% 
Parotid 65%   126 
Table 12 - Distribution of nodal location 
  Total Nodes  post-auricular  mastoid  parotid  pre-auricular  deep cervical  superficial cervical 
Max  10  2  2  7  3  6  2 
Average  4.2  0.2  0.3  2.7  0.3  0.5  0.1 
Min  2  0  0  0  0  0  0 
Total  117 (100%)  7   (6.0%)  8   (6.8%)  76 (65%)  9   (7.7%)  15 (12.8%)  2     (1.7%) 
Cases present  28 (100%)  6    (21%)  6   (21%)  26 (93%)  7     (25%)  9  (32%)  1      (3.6%)   127 
Table 13 - Identification of Nodes 
  Hot and Blue  Cold and Blue  Hot and Pale  Cold and Pale 
Maximum per patient  10  1  6  1 
Average per patient  3  0.07  0.89  0.14 
Minimum per patient  1  0  0  0 
Total in all patients  84  2  25  4   128 
 
Figure 29 – A flap raised showing the position of the greater auricular nerve and blue stained nodes 
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Follow-up Period 
No  patients  have  to  date  developed  evidence  of  lymph  node 
metastases.  Four  have  completed  36  months  follow-up,  seven 
have completed 30 months, ten have completed 24 months and 
seven, 18 months.  
One patient has developed a second primary tumour on the same 
auricle.  This  tumour  is  2cm  distant  to  the  site  of  the  previous 
tumour and for that reason is not believed to be local recurrence. 
This was treated with local excision only.   130 
Discussion 
Summary of Findings 
The  metastatic  rate  in  this  series  is  0  with  a  95%  confidence 
interval  of  0-12%.  No  patient  has  subsequently  developed 
evidence of lymph node metastases in the follow up period. 
The  finding  of  non-viable  tumour  cells  in  one  lymph  node 
demonstrates  that  the  correct  identification  of  target  nodes  has 
been achieved with this technique. 
Three  lymphatic  pathways  were  encountered  one  draining  from 
the anterior auricle to pre-auricular and superficial cervical nodes; 
a second one draining from behind the auricle to pre-mastoid and 
parotid  nodes  and  thirdly  posterior  to  this  a  pathway  to  post-
auricular and deep cervical nodes which traverses the insertion of 
sternocleidomastoid.  
Lymph  nodes  were  encountered  at  various  points  along  these 
pathways.  The  commonest  location  of  lymph  nodes  was  in  the 
parotid gland. 
The complication rate is high mainly due to wound infections. The 
use  of  suction  drains  and  peri-operative  antibiotics  significantly 
reduced post-operative infection.   131 
Strengths and Weaknesses of this Study 
The zero rate of metastatic spread detected in this study is both a 
strength  and  a  weakness.  On  one  hand  it  had  shown  that  the 
routine use of sentinel lymph node biopsy in these tumours is not 
justified. On the other hand one or more positive results would 
have  given  greater  validation  to  the  technique  and  provided 
information  about  whether  early  detection  of  metastatic  spread 
conferred  long-term  benefit  to  the  patient.  A  larger  number  of 
patients  recruited  to  the  study  would  eventually  have  yielded 
positive  sentinel  nodes  and  with  this  may  have  come  some 
information about the characteristics of the primary tumour that 
correlated  with  a  high  risk  of  metastatic  spread.  The  high 
complication rate re-enforces the argument against sentinel lymph 
node biopsy unless there is a high risk of metastatic spread. 
Useful information has been provided on the technical aspects of 
the  procedure  including  the  likely  location  of  nodes.  This  is 
applicable to all malignant tumours of the auricle to which sentinel 
lymph  node  biopsy  can  be  applied  notably  melanoma. 
Additionally the specific details of the lymphatic drainage of these 
tumours have significant implications for performing either elective 
or therapeutic neck dissections for potential or definitive metastatic 
spread. To excise the lymph nodes identified here will require an 
extended  neck  dissection  encompassing  the  superficial  parotid 
gland,  the  post-auricular  and  mastoid  nodal  groups.  Complete 
removal of these latter two groups will require the removal of the 
upper  portion  of  sternocleidomastoid  from  the  mastoid  and 
clearing  of  the  mastoid  to  a  sub-periosteal  level  on  the  lateral, 
inferior and anterior surfaces.  
It  impossible  to  currently  exclude  the  possibility  that  one  of  the 
patients in this series will subsequently develop metastases as not   132 
all have yet achieved two years of follow up although follow-up for 
all patients is continuing. 
Comparison With The Work Of Others 
The metastatic rate of zero is not comparable with the previously 
reported retrospective series looking at squamous cell carcinoma 
of the auricle nor the historic rate within our unit.
2,  3,  36,  38,  66 It is 
possible  that  the  metastatic  rate  in  this  series  has  in  some  way 
been influenced by the study. All patients in this study were treated 
somewhat more quickly than would have normally been expected 
within  our  unit.  This  has  happened  because  the  research  was 
carried out by a dedicated research fellow with dedicated theatre 
time allocated to research cases. This meant that all cases were 
usually seen within a week of referral and operated on within a 
further week. This compares with our normal protocol for referrals 
such as these that would have a clinic appointment 2 – 4 weeks 
from  referral  and  be  scheduled  for  surgery  in  3  –  4  weeks 
following this.  
Byers previously noted in his retrospective review of ASCC that a 
previous history of cutaneous malignancy conferred a lower risk of 
developing LNM.
2 There are several possible explanations for this 
and no conclusions were drawn from it at the time. It is possible 
that patients with a previous history of skin malignancy were able 
to be treated earlier because they were already under the care of 
a  dermatologist  or  surgeon  and  knew  the  nature  of  the  lesion. 
There  is  not  sufficient  information  available  about  ASCC  to 
determine whether a delay in treatment of a few weeks is sufficient 
to alter the metastatic rate. Mackie did however show that early 
referral  for  melanoma,  within  three  months  of  first  noticing  the 
lesion, did significantly reduce the Breslow thickness of the tumour   133 
which  is  a  well  established  and  accurate  predictor  of 
metastases.
104  
Unlike other authors who have previously performed sentinel node 
work involving the parotid gland we have not found it necessary to 
perform  superficial  parotidectomies  in  order  to  harvest  the 
nodes.
105 In our series we found it possible to achieve dissection of 
the sentinel node(s) and reduction of radiation levels in the basin 
to  a  background  level  without  the  need  to  remove  additional 
tissue. This confirms what has recently been reported by Loree et 
al  in  melanoma  where  SNB  did  not  complicate  a  further 
completion  superficial  parotidectomy  with  sparing  of  the  facial 
nerve.
106 
Meaning of the Study 
This study has demonstrated that sentinel lymph node biopsy for 
auricular squamous cell carcinoma is technically possible but does 
have a complication rate. This means that if this intervention is to 
be offered to patients that the potential benefits of the procedure 
must  be  weighed  against  these  complications  as  well  as  the 
additional  hospital  stay,  operation  length  and  wound  size.  The 
only  benefit  that  any  patient  in  this  series  has  had  is  the  re-
assurance  that  a  negative  sentinel  node  biopsy  can  offer.  The 
reassurance can now be based on the fact that to date there have 
been no false negative results. 
This  study  shows  that  there  is  no  case  for  the  routine  use  of 
sentinel lymph node biopsy in auricular squamous cell carcinoma. 
Currently  sentinel  lymph  node  biopsy  remains  a  potentially 
interesting research tool in the management of these tumours but 
more  work would  need  to be  carried  out  to  validate  its  routine 
clinical use. Particularly any method of stratifying patients into a   134 
high-risk  group  as  this  could  alter  the  cost-benefit  ratio  for  the 
patient. 
The lymphatic pathways encountered in this study and the location 
of the sentinel nodes have implications for performing elective or 
therapeutic neck dissections for primary squamous cell carcinoma 
of the auricle. A comprehensive resection in addition to a standard 
modified  radical  neck  dissection  should  include  the  superficial 
parotid gland and overlying superficial nodes, the post-auricular 
node(s), the mastoid nodes, the sternocleidomastoid muscle and 
the periostium from all sides of the mastoid bone. The resection 
could  be  facilitated  by removal  of  the  mastoid  process  and  the 
upper end of sternocleidomastoid. 
Unanswered Questions and Future Research 
Future  research  in  this  field  should  concentrate  on  identifying 
patients most at risk of developing metastatic spread from these 
tumours.  If  this  could  be  done  and  high-risk  patients  identified 
then a further study could re-evaluate the use of sentinel lymph 
node biopsy in these patients. The number of patients required for 
such a study would either require a long recruitment period or a 
multi-centre study. 
It may be that if tumours can be identified as having a significant 
risk of metastatic spread that a staging neck dissection should be 
carried out instead  of  sentinel lymph node biopsy. This has the 
advantage  of  potentially  being  therapeutic  for  early  lymphatic 
spread  and  prevents  the  need  for  secondary  procedures  in  the 
event of a positive sentinel node biopsy. It would be interesting to 
compare the complication rate of such an approach with that of 
sentinel node biopsy as a perceived lower complication rate is one 
of the main reasons that sentinel node biopsy has gained favour 
in recent years.   135 
Conclusions 
Sentinel  lymph  node  biopsy  should  not  be  routinely  used  in 
squamous cell carcinoma of the auricle. The technique is validated 
but  the  high  complication  rate  and  low  detection  of  metastatic 
spread means that the  cost outweighs the benefit. If patients at 
high risk of metastatic spread can be identified it could be used in 
place of an elective neck dissection and target specific nodes. 
The  location  of  the  sentinel  nodes  and  lymphatic  drainage 
pathways of the auricle mean that a standard neck dissection is 
not  an  adequate  operation  for  elective  staging  or  therapeutic 
treatment in cases of metastatic spread and it must be extended to 
encompass specific nodal locations.   136 
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Summary 
Introduction 
Squamous cell carcinoma is known to be associated with a high 
risk of metastatic spread which is often fatal. Identification of high-
risk tumours would allow prophylactic treatment to the lymph node 
basins but there are not yet any agreed criteria for this. 
Materials and Methods 
A retrospective analysis of 229 cases of squamous cell carcinoma 
of the auricle and histological features of the tumours.  
Results 
Metastasis  occurred  in  10.5%  of  cases.  66.7%  of  patients  who 
developed  metastases  died  as  a  result  of  them  despite  multi-
modality treatment. Tumours with a depth of invasion greater than 
8mm or a depth of invasion between 2-8mm in conjunction with 
evidence of cartilage invasion, lymphovascular invasion or a non-
cohesive invasive front are at high risk of metastasis. 
Conclusions 
Patients  with  high  risk  tumours  should  be  considered  for 
prophylactic  therapy  to  or  staging  of  the  regional  lymph  nodes 
carried out.   138 
Introduction 
Squamous cell carcinoma of the auricle has long been recognised 
as a malignancy with specific problems.
8 It is known to metastasise 
to  the  regional  lymph  nodes  more  frequently  than  comparable 
tumours at other sites.
1-3, 16, 36, 38, 42, 45, 65-67 It is also recognised that 
patients commonly die as a result of this metastatic spread and 
auricular  squamous  cell  carcinoma  is  a  leading  cause  of  death 
from  non-melanoma  skin  cancer.
107  Despite  the  high  mortality 
from  metastasis  there  is  no  consensus  of  opinion  as  to  when 
prophylactic treatment should be carried out in the clinically node 
negative patient
108 and previous publications that have suggested 
indications  such  as  cartilage  invasion,  aggressive  mode  of 
invasion  and  tumour  size  have  not  been  supported  in  large 
series.
1-3 
In our practice we accept a 20 % risk of metastasis as sufficient 
indication  to  offer  prophylactic  treatment  to  the  lymph  node 
basins. This is based upon previous cost-benefit analyses carried 
out  for  malignancies  of  the  upper  aero-digestive  tract  which 
although not directly comparable to cutaneous malignancies do 
spread  to  similar  nodal  locations.
72,  85  More  recent  publications 
have  suggested  that  this  threshold  should  be  lowered  to  15% 
because  advances  in  peri-operative  care  have  decreased  the 
morbidity and mortality associated with neck dissections.
73 Thus in 
order  to  provide  useful  prognostic  value  any  indicators  for 
prophylactic  treatment  should  carry  a  risk  of  at  least  15%  but 
preferably 20%. 
The current treatment policy in our unit is to treat metastases only 
when they become clinically apparent, as we do not believe there 
is  sufficient  evidence  to  support  the  use  of  elective  lymph  node 
dissections in these patients.   139 
The Setting of The Study 
It is important to understand the setting in which this study took 
place as this is key to understanding and interpreting the results. 
Canniesburn  Plastic  Surgery  Unit  is  a  regional  service  which 
provides both secondary and tertiary referrals for plastic surgery 
for the West of Scotland. It serves a population of approximately 
3.5 million or 60% of the Scottish population. The unit operates on 
a ‘hub and spoke’ configuration with one central unit at Glasgow 
Royal  Infirmary  where  in-patient  work  is  carried  out.  Outpatient 
clinics  and  operating  sessions  are  held  in  multiple  hospitals 
around  the  West  of  Scotland.  Patient  casenotes  are  maintained 
independently in each hospital. 
The  design  of  the  service  is  such  that  patients  with  auricular 
squamous  cell  carcinoma  could  initially  be  seen  and  have  all 
treatment  and  follow-up  in  the  base  unit  or  at  one  of  the 
peripheral hospitals. They may also have been transferred to the 
base unit for treatment but had follow-up in a peripheral hospital. 
There is also a sub-speciality multidisciplinary head and neck clinic 
held in the base unit to which it would be expected that all patients 
who  develop  lymph  node  metastasis  from  a  primary  auricular 
squamous cell carcinoma are referred from peripheral clinics. 
Patients for this study were identified from the pathology database 
at Glasgow Royal Infirmary and therefore represent only a subset 
of all patients referred to our service. The pathology department 
recorded all specimen reports in one computer database that ran 
from  1992  to  2006.  This  database  is  coded  for  diagnosis  and 
anatomical site. Unfortunately skin is one anatomical site and no 
subdivision is made of this in the coding. This design makes it easy 
to  find  all  squamous  cell  carcinomas  from  the  skin  but  not 
specifically from the auricle.   140 
Materials and Methods 
Ethical  approval  was  obtained  from  the  local  ethics  committee. 
The  study  aimed  to  identify  as  many  patients  as  possible  with 
auricular squamous cell carcinoma. A computer script was written 
to interrogate the pathology database that identified all cutaneous 
squamous cell malignancies from inception of the database until 
August  2004.  This  cut-off  date  allowed  for  two  year  follow  up 
during which time the majority of metastases would be expected to 
present.  The  script  then  searched  the  text  of  each  report  for  a 
matching word from the following list; auditory, auricular, auricle, 
concha,  conchal,  ear,  helical,  helix,  scapha,  scaphoid,  tragal, 
tragus and triangular. The script was design in such a way that 
helix  would  also  pick  up  antihelix  or  anti-helix,  etc.  Since  the 
information provided on the request form stating the location of 
the  excision  was  included  in  the  text  of  the report  we  could  be 
reasonable certain that this method would identify most cases of 
auricular squamous cell carcinoma. It was inevitable that this list 
would also include some cases that were not of interest e.g. where 
a patient had undergone excision of a ‘dog ear’ or ‘pre-auricular’ 
lesion. Peri-auricular tumours were not included in this study. All 
cases were believed to have an origin on the auricle itself. 
The database provided a list of patients whose case notes were 
then obtained and pathology reports examined to ensure that the 
patient had been correctly identified. At this stage any incorrectly 
identified  patients  were  removed  from  the  study.  A  spreadsheet 
was then set up to record pertinent details about the patient and 
primary tumour. Cases of Fergusson-Smith disease were excluded. 
A note was also made if the patient was on immunosuppressive 
medication  or  was  known  to  suffer  from  a  haematological 
malignancy.    141 
Histopathological Analysis 
It quickly became apparent while processing case notes that many 
of the original pathology reports were lacking in sufficient detail to 
allow meaningful analyses to be carried out. Details such as depth 
of invasion and invasion of nerves and vessels were often missing 
from reports. The original pathology of all primary specimens that 
had  been  processed  at  Glasgow  Royal  Infirmary  pathology 
department  was  therefore  reviewed  by  one  pathologist  (Keith 
Hunter  –  Lecturer  in  Pathology,  University  of  Glasgow).  No 
additional pathological processing or  staining of any specimens 
was carried out. The aim was to fully report the original specimen 
as  if  it  had  originally  been  processed  in  accordance  with  the 
minimum dataset in the Royal College of Pathologist guidelines for 
skin  SCC.
109  The  specific  details  recorded  were  length  and 
breadth of the tumour (excluding any adjacent dysplasia), overall 
tumour  thickness,  depth  of  invasion  (from  level  of  original 
epidermal surface), any histological subtype, degree of histological 
differentiation, presence of tumour invasion of nerves, vessels or 
cartilage.  Cartilage  invasion  was  sub-classified  into  tumour  that 
had  caused  smooth  erosion  in  the  cartilage  as  if  by  tumour 
expansion and tumour that was clearly invading destructively into 
the  cartilage.  The  tumour  was  also  categorised  as  having  a 
cohesive or non-cohesive invasive front based upon the criteria set 
out in Royal College of Pathologists Guidelines for Head and Neck 
Malignancy.
110  Completeness  of  excision  was  also  reported  and 
categorised as completely excised, tumour extending to margin or 
margins felt to be close, where completeness of excision was in 
doubt usually less than 0.5mm. 
Statistical Analysis 
Statistical analysis was carried out using SPSS software.   142 
Results 
A  total  of  393  records  were  identified  from  the  pathology 
database. 42 sets of case notes were not obtainable. 7 cases of 
Fergusson-Smith disease were excluded. 229 cases of squamous 
cell carcinoma in 221 patients had the primary site confirmed as 
being on the auricle. 9 of these cases were referred to our central 
unit with recurrent disease having had a previous auricular tumour 
excised elsewhere. Only 5 patients were female giving a male to 
female  ratio  of  23:1.  Only  one  case  was  treated  by  primary 
radiotherapy after having a diagnostic biopsy. All remaining 228 
cases were treated initially by surgical excision. One case received 
immediate  post-operative  radiotherapy  because  of  involved 
resection margins. Age ranged from 47.9 to 93.5 years old with a 
median of 78. 
The helix was by far the most common sub-site with 57% of cases 
occurring  here.  (Figure  28)  The  sub-site  was  not  able  to  be 
accurately determined in 38 cases. It was not possible to correlate 
site  of  primary  tumour  with  development  of  metastases  or  the 
location at which metastases appeared. 
Forty  patients  died  during  follow  up.  (Table  14)  Follow  up 
information  was  available  for  a  minimum  two  years  in  66.  A 
significant  number  of  patients  were  followed  up  in  peripheral 
hospitals.   143 
 
Table 14 - Length of Follow Up 
Length of Follow up  Number of patients 
>24 months  66 (14 died during follow up) 
12-24 months  40 (12 died during follow up) 
6-12 months  28 (5 died during follow up) 
< 6 months or followed 
up in peripheral unit 
87 (9 died during follow up) 
Total  221 (40 died during follow up)   144 
 
 
Figure 30 - Site of Primary Tumours 
 
Posterior 
surface 
20 cases 
(8.7%)  Helix 
131 cases 
(57.2%) 
Antihelix 
25 cases 
(10.9%) 
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(3.9%) 
Tragus 
2 cases 
(0.9%) 
Earlobe 
4 cases 
(1.7%) 
Not 
recorded 
38 cases 
(16.6%)   145 
Metastasis 
25 cases developed lymph node metastases. One of these had a 
confounding primary tumour on the temple, which was felt to be 
the  likely  source  of  metastases  reducing  the  number  of  cases 
where  the  definite  source  was  a  primary  auricular  tumour.  This 
gives a rate of 24 in 229 or 10.5%. Six of these cases were among 
the 9 referred from other units with recurrent disease. 18 of the 
220 (7.9%) cases where the primary tumour was excised in our 
central unit developed metastases.  
Of the 24 patients with lymph node metastases from an auricular 
primary,  8  had  metastases  at  the  time  of  presentation.  Time  to 
presentation of metastases for the remaining 16 ranged from 10 
to  149  weeks  with  a  median  time  of  36  weeks.  11  presented 
within  1  year  of  original  surgery.  Only  one  case  developed 
metastases after two years from initial presentation. 
The  parotid  gland  was  the  commonest  site  of  lymph  node 
metastases followed by level II of the neck and the mastoid/post-
auricular nodal group. (Figure 29) Disease initially presented at 
one  of  these  sites  prior  to  progression  elsewhere  in  the  neck. 
Disease was subsequently found in Levels I & III – V of the neck. 
Four patients (1.7%) developed distant metastatic spread following 
the  development  of  lymph  node  metastases.  The  sites  where 
distant  metastases  occurred  were  the  brain,  lung,  lumbar  spine 
and skin of the shoulder. No patient developed distant metastases 
without  first  developing  regional  lymph  node  metastases.  All 
patients with distant metastases died of disease. 
Treatment of the lymph node metastases varied considerably. One 
patient  was  palliated  only;  two  were  treated  with  radiotherapy 
only.  Ten  were  treated  with  surgery  only  and  eleven  received 
combination  treatment  with  surgery  and  post-operative   146 
radiotherapy. A total of 12 parotidectomies were carried out 8 in 
combination  with  a  neck  dissection.  9  neck  dissections  not 
including  the  parotid  were  carried  out.  It  was  not  possible  to 
correlate treatment modalities with survival. Two patients treated 
initially with only superficial parotidectomies subsequently required 
neck dissections. 
Mortality 
15  patients  died  as  a  direct  result  of  Auricular  Squamous  Cell 
Carcinoma, 1 as a result of locally invasive disease, 9 as a result 
of failure of loco-regional control  and 4 who developed distant 
metastases.  An  additional  2  patients  died  as  a  complication  of 
their  treatment.  Therefore  17  of  229  (7.5%)  died  as  a 
consequence of auricular squamous cell carcinoma. 16 of the 24 
(66.7%) patients who developed lymph node metastases died as a 
result of their disease. 
It is not possible to provide accurate figures of mortality from other 
causes due to the number and geographical spread of patients in 
the series who were followed up in peripheral hospitals. 
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Figure 31 - Location of Metastases 
The percentages show the rate of involvement of each nodal basin 
in the 24 cases with lymph node metastasis. 
Level IV 
2 cases 
(8.3%) 
Level III 
4 cases 
(12.5%)  Level V  
3 cases 
(12.5%) 
Level I 
1 case 
(4.2%) 
Level II 
10 cases 
(41.7%) 
Parotid 
13 cases 
(54.2%) 
Mastoid / Post-
Auricular  
7 cases (29.2%)   148 
Tumour Dimensions 
A total of 219 cases had the pathology of the primary specimen 
reviewed.  This  represented  228  cases  treated  by  initial  surgical 
resection  minus  9  cases  referred  with  recurrent  disease  after 
resection  of  primary  tumour.  6  cases  were  excluded  from  this 
analysis because the tumour dimensions were unobtainable due to 
fragmentation or processing of the specimen. This left 213 cases 
of which 18 had metastasised. One patient with metastasis had a 
confounding primary tumour on his temple that was felt likely to 
be the source of metastasis and was removed from the analysis 
leaving a total of 212 cases (in 207 patients). The 17 remaining 
cases  were  metastases  from  primary  untreated  auricular 
squamous cell carcinoma. 
Initial examination of the data showed that the tumours that had 
metastasised tended to be larger and invade deeper. It was also 
obvious that there were several large superficial tumours that did 
not  metastasise  and  several  small  tumours  that  invaded  deeply 
that did not metastasise. Two calculated figures were created in 
the  data;  the  product  of  the  length  and  the  breadth;  and  the 
product of the length breadth and depth of invasion. These figures 
are proportional to the tumour area and volume respectively but 
not exact calculations of them. 
Statistical analysis of these factors was carried out using a Mann-
Whitney U test as the data was not normally distributed. (Figure 30 
& Tables 15 - 17) 
Tumour length, breadth, depth of invasion and volume were all 
predictive of development of metastases with p values of <0.001. 
Tumour  thickness  was  also  predictive  with  a  p  value  of  0.013. 
(Table 17) 
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Figure  32  -  Boxplot  of  Depth  of  Invasion  In  Tumours 
That Metastasised and That Did Not Metastasise   150 
Table 15 - SPSS Output Table - Descriptive Statistics 
  N  Mean  Std. Deviation Minimum  Maximum  Percentiles       
                  25th  50th (Median) 75th 
LENGTH  212  16.8  10.8  1.00  70.0  9.00  15.0  23.8 
BREADTH  212  12.5  7.64  1.00  40.0  7.00  10.0  17.0 
DEPTH  212  3.75  2.55  .50  16.0  2.00  3.00  5.00 
THICKNESS  212  5.05  3.35  .50  20.0  2.50  4.50  6.50 
AREA  212  278  340  1.00  2400  60.0  144  400 
VOLUME  212  1410  2850  1.00  21600  150  441  1290   151 
 Table 16 - SPSS Output Table - Ranks 
   Metastases Number  Mean Rank  Sum of Ranks 
LENGTH  Yes  17  159.88  2718.00 
   No  195  101.85  19860.00 
   Total  212     
BREADTH  Yes  17  157.65  2680.00 
   No  195  102.04  19898.00 
   Total  212     
DEPTH  Yes  17  162.68  2765.50 
   No  195  101.60  19812.50 
   Total  212     
THICKNESS  Yes  17  141.53  2406.00 
   No  195  103.45  20172.00 
   Total  212     
AREA  Yes  17  161.76  2750.00 
   No  195  101.68  19828.00 
   Total  212     
VOLUME  Yes  17  167.00  2839.00 
   No  195  101.23  19739.00 
   Total  212     
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Table 17 - SPSS Output Table - Test Statistics 
  LENGTH  BREADTH  DEPTH  THICKNESS  AREA  VOLUME 
Mann-Whitney U  750.000  788.000  702.500  1062.000  718.000  629.000 
Wilcoxon W  19860.000  19898.000  19812.500  20172.000  19828.000  19739.000 
Z  -3.748  -3.593  -3.959  -2.461  -3.874  -4.240 
Asymp. Sig. (2-tailed)  .000  .000  .000  .014  .000  .000 
Grouping Variable: Metastases 
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Tumour Volume 
Tumour  volume  (length  x  breadth  x  depth  of  invasion)  was  the 
most  predictive  of  metastases  with  the  lowest  Mann-Whitney  U, 
Wilcoxon W and Z values (Table 16). There was a sharp cut off in 
the data at 2500mm
3 with 12 of 31 tumours (38.7%) greater than 
this in volume having metastasised. (Table 18) The five remaining 
cases of metastases ranged in volume from 189 to 836mm
3. All 
five  of  these  tumours  had  adverse  histological  features  that  are 
discussed later.   154 
 
Table 18 - Metastatic Rates Stratified by Tumour Volume 
Tumour Volume 
(Length  x  breadth  x 
depth) 
Total Cases  Metastatic Cases 
(Rate) 
>10,000mm
3  5  3 (60%) 
5,000 – 10,000mm
3  9  5 (55.6%) 
2,500 – 5,000mm
3  17  4 (23.5%) 
1,000 – 2,500mm
3  38  0 
500 – 1,000  28  1 (3.5%) 
250 - 500  37  2 (5.4%) 
150 - 250  26  2 (7.7%) 
<150  52  0 
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Depth of invasion  
Depth of invasion was the next most useful measure. A useful cut-
off  occurred  at  7  mm.  (Table  19)  10  of  21  (47.6%)  tumours 
greater than 7mm thick had metastasised. 
All 10 metastatic cases that would have been predicted by using 
the 7mm depth cut off were also predicted by the volume cut off at 
2500mm
3  but  the  volume  method  also  included  the  two 
metastases that occurred in large tumours between 5 and 7mm 
deep. 
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Table  19  -  Metastatic  Rates  Stratified  by  Depth  of 
Invasion 
Depth of Invasion  Total Cases  Metastatic cases 
(Rate) 
10mm +  8  3 (37.5%) 
9-9.9mm  4  3 (75%) 
8-8.9mm  4  3 (75%) 
7-7.9mm  5  1 (20%) 
6-6.9mm  12  1 (8.3%) 
5-5.9mm  23  1 (4.3%) 
4-4.9mm  37  1 (2.7%) 
3-3.9mm  32  1 (3.1%) 
2-2.9mm  52  2 (3.8%) 
<2mm  35  0 
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Adverse Histological Features 
Cartilage Invasion 
29 tumours showed definite destructive invasion of the auricular 
cartilage.  7  (24.1%)  of  these  metastasised.  A  further  9  tumours 
showed  superficial  erosion  of  the  cartilage  only.  None  of  these 
metastasised. 174 remaining tumours did not invade the cartilage 
10 (5.7%) of these metastasised. (Figures 31 -38) For the purposes 
of analysis the tumours with superficial erosion only were grouped 
with tumours that did not invade cartilage. A Fisher’s Exact test 
showed a positive correlation between Cartilage Destruction and 
development of metastases p-value = 0.003. 
  Cartilage 
Destruction 
No  Cartilage 
Destruction 
Total 
Metastases  7  10  17 
No 
Metastases 
22  173  195 
Total  29  183  212 
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Figure 33 - Tumour abutting cartilage with compression 
of the peri-chondrium. H&E stain. 
 
Figure 34 - Close-up of tumour abutting cartilage.   159 
 
Figure  35  -  Tumour  showing  smooth  erosion  of  the 
cartilage. H&E stain. 
 
Figure 36 - Close-up of tumour erosion of cartilage.   160 
 
Figure  37  -  Superficial  erosion  of  the  cartilage.  H&E 
stain. 
 
Figure 38 - Close-up of superficial cartilage erosion.   161 
 
Figure  39  -  Tumour  showing  destruction  of  cartilage 
with loss of perichondrium and destructive loss of bulk. 
H&E stain. 
 
Figure 40 - Close-up of cartilage destruction. 
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Lymphovascular Invasion 
Four cases showed evidence of lymphovascular invasion. Two of 
these  metastasised  and  both  patients  died  as  a  result  of  the 
disease with distant metastatic spread. There was only one other 
case in the series that developed distant metastases. Both of these 
tumours were small with volumes of 210 and 300mm
3 and both 
invaded  to  a  depth  of  2mm.  The  vessels  in  both  metastasising 
cases were felt to be to be lymphatic vessels (Figure 39) as only 
endothelial structures were seen and in contrast the vessels in the 
non-metastasising  cases  was  felt  to  be  vascular  as  there  was  a 
more obvious vascular structure (Figure 40). In three other cases 
lymphovascular  invasion  was  thought  to  be  possible  but  not 
definitely identified. None of these cases metastasised. A Fisher’s 
Exact test showed a positive correlation between Lymphovascular 
Invasion  and  development  of  metastases  with  a  p-value  = 
0.0331. 
  Lymphatic 
Invasion 
No  Lymphatic 
Invasion 
Total 
Metastases  2  15  17 
No Metastases  2  193  195 
Total  4  208  212 
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Figure  41  -  Tumour  Invasion  of  a  Lymphatic  Vessel. 
H&E stain   164 
 
Figure 42 - Tumour invasion of a vascular channel. H&E 
stain.   165 
Perineural Invasion 
A total  of  16  cases showed definite perineural invasion. (Figure 
41) Three (18.8%) of these metastasised. A further four showed 
possible  but  not  confirmed  perineural  invasion  of  which  one 
metastasised.  A  Fisher’s  Exact  test  did  not  show  a  correlation 
between Perineural Invasion and development of metastases with 
a p-value = 0.124. 
  Perineural 
Invasion 
No  Perineural 
Invasion 
Total 
Metastases  3  14  17 
No Metastases  13  182  195 
Total  16  196  212 
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Figure 43 - Peri-neural invasion. H&E stain.   167 
Non-cohesive Invasive Front 
A total of 23 cases had a non-cohesive invasion front. (Figures 42 
& 43) In 10 of these this was only present focally. (Figures 44 & 
45) Six of the 23 (26.1%) metastasised including 2 of 10 (20%) 
where the non-cohesive front was only present focally. A Fisher’s 
Exact test showed a positive correlation between a non-cohesive 
invasive  front  and  development  of  metastases  with  p-value  = 
0.005. 
  Non-cohesive 
front 
Cohesive front  Total 
Metastases  6  11  17 
No Metastases  17  178  195 
Total  23  189  212   168 
 
Figure 44 - A non-cohesive invasive front. H&E stain. 
 
Figure 45 - Close-up of non-cohesive invasive front.   169 
 
Figure  46  -  A  focally  non-cohesive  invasive  front.  H&E 
stain. 
 
Figure 47 - Close-up of a focally non-cohesive invasive 
front. 
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Combining  Tumour  Volume  and  Depth  With 
Adverse Histological Features 
Only  tumours  greater  than  2500mm
3  in  volume  metastasised 
without evidence of cartilage invasion, lymphovascular invasion or 
a  non-cohesive  invasive  front.  No  tumours  less  than  150mm
3 
metastasised despite adverse histological features. It was therefore 
possible  to  stratify  tumours  into  three  volume  groups  and 
subdivide them by adverse histological features. (Table 20) 
Similarly it was possible to stratify tumours on the basis of depth of 
invasion. Tumours over 8mm deep metastasised without evidence 
of  cartilage  invasion,  lymphatic  invasion  or  a  non-cohesive 
invasive front. No tumours below 2mm deep metastasised despite 
adverse histological features. (Table 21) 
The  combination  of  depth  of  invasion  over  8mm  and  depth  of 
invasion 2-8mm with adverse histological features included all 17 
cases in this series that metastasised and another 32 cases that 
did  not  spread  to  the  lymph  nodes.  This  was  better  than  the 
combination  of  volume  and  adverse  histological  features  which 
also included all metastatic cases and another 38 non-metastatic 
cases. (Table 22) 
The mortality was worse in the tumours that were included on the 
basis  of  intermediate  volume  or  depth with adverse  histological 
features.  Mortality  from  these  tumours  was  87.5%  -  100% 
compared with 41% - 44% for tumours that were included on the 
basis of volume or depth of invasion alone. (Table 23)   
   171 
Table 20 - Combining Tumour Volume With Adverse Histological Parameters 
  Total Number of Cases  Metastatic Cases (Rate) 
Tumours > 2,500mm
3  31  12 (38.7%) 
With cartilage destruction, lymphovascular 
invasion or non-cohesive front 
17  7 (41.2%) 
Without cartilage destruction, lymphovascular 
invasion or non-cohesive front 
14  5 (35.7%) 
Tumours 150 – 2,500mm
3  129  5 (3.9%) 
With cartilage destruction, lymphovascular 
invasion or non-cohesive front 
24  5 (20.8%) 
Without cartilage destruction, lymphovascular 
invasion or non-cohesive front 
105  0 
Tumours <150mm
3  52  0   172 
Table 21 - Combining Tumour Depth of Invasion With Adverse Histological Parameters 
  Total Number of Cases  Metastatic Cases (Rate) 
Tumours > 8mm
  16  9 (56.2%) 
With cartilage destruction, lymphovascular 
invasion or non-cohesive front 
10  4 (40%) 
Without cartilage destruction, lymphovascular 
invasion or non-cohesive front 
6  5 (83.3%) 
Tumours 2 -8mm  161  8 (5.0%) 
With cartilage destruction, lymphovascular 
invasion or non-cohesive front 
33  8 (24.2%) 
Without cartilage destruction, lymphovascular 
invasion or non-cohesive front 
128  0 
Tumours < 2mm  35  0   173 
 
Table 22 - Comparison of Metastatic Rates in High Risk Tumours Identified by Volume and Depth of Invasion 
  Total Number of Cases  Metastatic Cases (Rate) 
Tumours > 2,500mm
3 & tumours 150 – 2,500mm
3 
with cartilage destruction, lymphovascular invasion 
or non-cohesive invasive front 
55  17 (30.9%) 
Tumours > 8mm deep & tumours 2-8mm deep with 
cartilage destruction, lymphovascular invasion or 
non-cohesive invasive front 
49  17 (34.7%) 
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Table 23 - Mortality from Metastases Stratified by High Risk Categories 
  Number of Cases With Metastases  Number Died of Disease 
Tumours > 2,500mm
3  12  5 (41.7%) 
Tumours  150  –  2,500mm
3  with  cartilage 
destruction,  lymphovascular  invasion  or  non-
cohesive front 
5  5 (100%) 
Tumours > 8mm deep  9  4 (44.4%) 
Tumours 2 - 8mm deep with cartilage destruction, 
lymphovascular invasion or non-cohesive front 
8  7 (87.5%) 
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Table 24 - Dimensions and Pathological Features of Tumours That Metastasised 
cartilage 
invasion 
lymphovascular 
invasion 
perineural 
invasion 
non-cohesive 
invasive front 
Length 
(mm) 
Breadth 
(mm) 
Depth of 
invasion (mm) 
Thickness 
(mm) 
Area 
(mm
2) 
Volume 
(mm
3) 
no  yes  no  no  15  10  2  2  150  300 
no  yes  no  no  15  7  2  2  105  210 
yes  no  no  no  13  10  2  2  130  260 
yes  no  no  no  9  7  3  3  63  189 
no  no  yes  yes  19  11  4  4  209  836 
no  no  no  yes  25  25  5  5  625  3125 
yes  no  no  yes  22  21  6  6  462  2772 
yes  no  no  no  22  22  7  7  484  3388 
yes  no  no  yes focally  40  20  8  8  800  6400 
no  no  no  no  25  25  8  8  625  5000 
no  no  yes  no  40  35  8  8  1400  11200 
yes  no  no  no  30  25  9  9  750  6750 
no  no  no  yes  60  40  9  9  2400  21600 
yes  no  yes  yes focally  30  27  9  9  810  7290 
no  no  no  no  34  24  10  10  816  8160 
no  no  no  no  24  9  12  12  216  2592 
no  no  possibly  no  42  25  15  15  1050  15750 
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Surgical Resection Margins & Local Recurrence 
In 24 cases the resection margin was found to be involved and in 
a further 8 the margin was felt to be close and completeness of 
excision was in doubt. 11 cases underwent wider excision and only 
one of these (9.1%) recurred locally. Four of 13 (30.8%) cases that 
did not receive further surgery recurred locally. Two cases (15.4%) 
with  dubious  resection  margins  recurred  at  the  level  of  the 
regional lymph nodes only. 
Six of 180 (3.3%) tumours that were thought to be fully excised 
developed local recurrence. A total of 11 tumours recurred locally. 
Four of these occurred in patients with lymphatic metastases. One 
synchronously,  one  after  treatment  of  lymph  nodes  and  two 
predated the lymphatic disease. 
Degree of Histological Differentiation 
Of the 17 metastasising primary tumours of the auricle, 2 were 
regarded  as  well  differentiated  (one  of  which  had  features 
suggestive of a keratoacanthoma), 9 moderately differentiated, 3 
moderate to poorly differentiated and 3 poorly differentiated. In 
total  there  were  39  well  differentiated,  16  well  to  moderately 
differentiated,  116  moderately  differentiated,  20  moderate  to 
poorly differentiated and 21 poorly differentiated tumours. (Table 
25) 
Histological subtypes present were acantholytic, spindle cell, clear 
cell, basoloid, sebaceous and sarcomatoid. 2 of 3 tumours with 
spindle  cell  features  metastasised.  No  other  subtypes  showed  a 
relationship with metastases.   177 
 
Table 25 - Metastatic Rates In Subgroups of Histological 
Differentiation 
Degree of 
Differentiation 
Total  Number  of 
Cases 
Metastatic Cases 
Well  39  2 (5.1%) 
Well-moderate  16  0 
Moderate  116  9 (7.8%) 
Moderate-poor  20  3 (15%) 
Poor  21  3 (14.3%) 
Total  212  17 (8.0%) 
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Discussion 
Summary of Findings 
Auricular  squamous  cell  carcinoma  metastasises  to  the  regional 
lymph  nodes  in  10.5%  of  cases.  Spread  to  these  nodes  is 
associated with a high mortality (66.7%) despite the common use 
of  combined  modality  treatment  once  metastases  are  detected. 
The  commonest  cause  of  mortality  is  failure  of  loco-regional 
control. 
Tumours  at  high  risk  of  development  of  metastasis  can  be 
identified on the basis of the depth of invasion or tumour volume 
in  conjunction  with  evidence  of  cartilage  destruction, 
lymphovascular invasion or a non-cohesive invasive front. Depth 
of invasion greater than 8mm or depth of invasion 2 - 8mm in 
conjunction with one of the adverse histological features includes 
all cases that have metastasised and a minimum number of non-
metastasising cases. The overall risk of metastasis from tumours 
identified by this method is 34.7%. 
Tumours between 2 – 8mm deep with adverse histological features 
carry a higher mortality than those over 8mm deep. 
Lymph node metastases appear initially in the parotid gland, level 
II  of  the  neck  or  the  mastoid/post-auricular  nodal  group.  After 
appearing at one of these sites further spread can occur to levels I 
and  III-V.  Regional  lymph  node  metastases  always  predate  the 
development  of  distant  metastases  which  occurs  in  1.7%  of  all 
cases and is uniformly fatal. 
Evidence of lymphovascular invasion on primary histopathology is 
strongly  correlated  with  the  subsequent  development  of  distant 
metastases.   179 
Strengths and Weaknesses of This Study 
This  study  has  provided  a  sufficient  sample  size  to  allow 
meaningful statistical analysis of tumour pathological features to 
be  carried  out.  It  has  allowed  the  development  of  strategic 
thresholds where treatment of the regional lymph nodes should be 
considered. 
The  metastatic  rate  in  this  series  is  probably  not  a  true 
representation of the rate in the general population as the unit is a 
tertiary referral service and is likely to have accumulated the most 
severe cases. 
It has not been possible to identify which treatments of lymph node 
metastases are of benefit nor is it possible to determine from this 
work  if  prophylactic  treatment  of  the  lymph  nodes  confers  a 
survival advantage.  
Some of the histological features have occurred in small numbers 
and  specific  features  may  prove  of  significance  if  a  sufficiently 
larger sample size was available.   180 
Comparison With The Work of Others 
Previous studies on these tumours have been unable to correlate 
depth of tumour invasion with the development of metastasis.
2,  3 
This may be due to the fact that they looked at Clark’s levels rather 
than a measured depth. If that system had been used in this study 
then there would have been no relationship shown. A measured 
depth  of  invasion  has  been  shown  to  be  a  particularly  useful 
prognostic indicator in melanoma.
70, 111 
Cartilage  invasion  in  auricular  squamous  cell  carcinoma  is  a 
disputed  prognostic  indicator.
1-3,  112  Only  Afzelius  has  suggested 
that this is sufficiently predictive of metastasis to warrant therapy to 
the  lymph  nodes  and  these  finding  were  not  upheld  by  larger 
series by Byers and Freedlander.
1-3 In this study cartilage invasion 
has been subdivided into two groups on the basis of whether or 
not  the  tumour  appears  to  be  actively  destroying  cartilage  or 
simply  causing  erosion  as  the  tumour  expands.  It  can  be 
understood why many tumours on the auricle cause some erosion 
of the cartilage given its proximity to the skin but we believe that 
active  destruction  of  the  cartilage  by  the  tumour  is  a  distinct 
feature suggestive of a more aggressive malignancy. 
Afzelius  also  promoted  mode  of  tumour  invasion  as  a  useful 
prognostic  indicator  with  a  four  level  scoring  system  but  other 
authors  have  not  found  this  useful.
1-3  There  is  guidance  on  the 
classification  of  cohesive  and  non-cohesive  invasive  tumour 
fronts
110  and  in  this  series  in  intermediate depth  tumours  it  has 
identified tumour with an increased metastatic potential.     181 
Meaning Of This Study 
Given  the  high  mortality  associated  with  the  development  and 
subsequent  treatment  of  lymph  node  metastases  prophylactic 
treatment to the lymph node basins or staging of them should be 
done at the time of initial presentation in order to try to contain the 
disease.  
All tumours with a depth of invasion of over 8mm should have 
therapy directed at the neck as should all tumours with a depth of 
invasion  between  2-8mm  with  evidence  of  cartilage  destruction, 
lymphovascular  invasion  or  a  non-cohesive  invasive  front  on 
histological examination of the primary tumour. The latter group 
are at higher risk of death due to disease. 
Treatment of the neck could consist of initial staging of the lymph 
nodes  followed  by  therapy  if  metastases  are  detected  or 
prophylactic therapy could be carried out with a complete neck 
dissection  or  radiotherapy.  Since  the  site  of  first  presentation  of 
lymph node metastases is the parotid gland, level II of the neck or 
the mastoid/post-auricular nodal group, a staging neck dissection 
would  need  to  include  these  nodal  groups  at  a  minimum.  A 
therapeutic neck dissection would need to include these regions 
plus  levels  I  and  III-V  of  the  neck.  Sentinel  lymph  node  biopsy 
could  also  be  considered  as  an  alternative  staging  method 
although this is not a proven technique for this malignancy.  
Radiotherapy  as  an  alternative  treatment  for  primary  auricular 
tumours does not allow full examination of the histological tumour 
features.  In  such  cases  a  diagnostic  biopsy  should  be  done  to 
confirm the depth of the lesion. Treatment of the neck should be 
done  on  the  same  criteria  as  listed  above  but  also  tumours 
between 2-8mm deep where the product of the tumour length x   182 
breadth x depth of invasion exceeds 2,500mm
3 should also have 
treatment extended to the neck. 
Where there is doubt about the excision margins of the primary 
tumour a wider excision should be performed as this reduces to 
rate  of  local  recurrence  from  30.8%  to  9.1%.  Doubtful  primary 
excision  margins  have  also  been  associated  with  subsequent 
development of lymph node metastases.   183 
Unanswered Questions and Future Research 
The primary aim of future research should be to prophylactically 
treat  the regional  lymph  node  basins  in  new  cases  of  auricular 
squamous cell malignancy meeting the defined high-risk criteria. It 
should determine if the criteria are valid, establish if prophylactic 
treatment confers a survival advantage and establish the ‘cost’ in 
terms of morbidity and mortality of prophylactic treatment to the 
lymph  nodes.  Given  the  high  mortality  associated  with  the 
development of lymph node metastases prophylactic treatment is 
likely to be of benefit.   184 
Conclusions 
Lymph node metastases occur in around 10% of cases of auricular 
squamous cell carcinoma. They are usually fatal. Tumours with a 
depth of invasion > 8mm have a 56.2% risk of metastatic spread. 
Tumours  with  a  depth  of  invasion  between  2  –  8mm  and  with 
evidence  of  cartilage  destruction,  lymphovascular  invasion  or  a 
non-cohesive  invasive  front  have  a  24.2%  risk  of  metastatic 
spread. Prophylactic therapy to or staging of the regional lymph 
nodes  should  be  carried  out  for  patients  with  tumours  in  these 
high-risk groups. Evidence of lymphatic invasion is predictive of 
subsequent development of distant metastasis. 
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Summary 
Malignant  tumours  of  the  auricle  are  known  to  have  a  higher 
metastatic rate than other skin tumour sites and surgical removal 
of the lymph nodes is often required. There is not yet any clearly 
defined or accepted elective or therapeutic neck dissection. This 
study analyses the evidence  from several clinical  series together 
with static and dynamic lymphatic studies to provide a structured 
approach to surgical resection of cervical lymphatics involved in 
metastases from auricular tumours.   187 
Introduction 
Malignant  tumours  of  the  skin  of  the  auricle  are  known 
metastasise  more  commonly  than  comparable  tumours  at  other 
sites.
2,  3,  16,  30,  32,  55,  60,  77-79 Squamous cell carcinoma at this site is 
thought to have a metastatic rate of around 11% and melanoma a 
rate of around 39.2%.
60 In our own unit the metastatic rate for 
SCC is 10.5% and two thirds of our patients died as a result of the 
metastatic spread. Surgical removal of metastases is a commonly 
required  procedure  and  failure  of  loco-regional  control  in 
auricular squamous cell carcinoma remains the leading cause of 
death from these lesions which can invade the bone of the base of 
the  skull  and  adjacent  nerves  and  blood  vessels.  If  a  neck 
dissection is to be of benefit, it is vital to ensure that all potential 
areas of metastatic disease are removed. 
The therapeutic procedure to remove involved lymph nodes for a 
head and neck cancer is a comprehensive neck dissection. When 
applied  to  malignant  tumours  of  the  auricle  this  would  be 
extended  to  include  the  parotid  gland  in  addition  to  the  other 
cervical lymph node basins.
1,  2 This procedure carries significant 
morbidity  and,  although  acceptable  for  involved  nodes,  it  is  no 
longer the favoured procedure for staging in the N0 neck. 
Selective lymph node dissections have been successful in staging 
cancers of the head and neck that are commonly associated with 
metastatic spread such as oral, pharyngeal, laryngeal, nasal and 
thyroid tumours. These cancers have all been studied in detail and 
there  is  significant  information  available,  which  allows  specific 
nodes to be excised in selected nodal basins. Auricular tumours, 
however, have not been studied in such great detail and there is 
no established pattern of selective nodal dissection for them.    188 
The high incidence of metastases has prompted several authors to 
promote  elective  lymph  node  dissections  for  squamous  cell 
carcinoma of the auricle on the basis of tumour size, depth and 
mode of invasion but there is no clear consensus of opinion.
1,  3 
Elective lymphadenectomy is a potentially useful procedure as it 
allows  staging  of  the  disease  and  removes  small,  sub-clinical 
deposits  of  metastatic  disease  before  they  involve  important 
structures at the base of skull or spread further to cause distant 
metastases.
1, 3 However elective lymphadenectomy for melanoma 
has not shown to have any benefit for patients and has therefore 
fallen out of favour in recent years.
60   189 
Materials and Methods 
Information  on  the  lymphatic  drainage  of  the  auricle  and 
metastatic  spread  of  auricular  tumours  was  analysed  from  four 
different sources. A systematic review was carried out which found 
three papers that were able to give detailed information on the 
location of spread of squamous cell carcinoma of the auricle. An 
internal  retrospective  study  of  squamous  cell  carcinoma  of  the 
auricle  treated  in  the  Canniesburn  Plastic  Surgery  Unit  over  a 
twelve year period produced 24 cases with spread to the regional 
lymph nodes available for study. A cadaveric static lymphatic study 
in  five  auricles  was  examined  and  dynamic  lymphatic  drainage 
information  was  available  from  a  study  of  sentinel  lymph  node 
biopsy in a further 28 cases of auricular squamous cell carcinoma.    190 
Results 
The systematic review and the retrospective study has shown that 
the  commonest  locations  for  metastatic  spread  are  the  parotid 
gland, upper cervical chains (level II) and the mastoid and post-
auricular  nodal  groups.
2,  3,  38  (Table  26)  These  studies  also 
demonstrated that disease had to be present at one of these sites 
before it occurred elsewhere in the neck with further spread in the 
neck to levels I and III-V. The same pattern of spread also holds 
true for melanoma which supports a model of stepwise metastatic 
progression from first echelon nodes. 
55, 60 
Disease  is  commonly  present  in  both  the  parotid  gland  and 
cervical chains  or post auricular nodes. Tumours  originating on 
the  posterior  auricle  may  metastasise  anteriorly  to  the  parotid 
gland  while  tumours  originating  on  the  anterior  auricle  may 
spread posteriorly. 
The  static  and  dynamic  lymphatic  mapping  studies  have  shown 
that first echelon lymph nodes draining the auricle can lie in the 
superficial parotid gland, superficial cervical chains overlying the 
parotid, in the post-auricular and mastoid region and upper deep 
cervical chain. The lymph nodes in the post-auricular and mastoid 
group represent specific surgical problems as the lymphatics and 
nodes lie adjacent to the periostium of the mastoid bone on its 
anterior and lateral surfaces. The lymphatics traverse the insertion 
of sternomastoid and lymph nodes may be located deep to the 
sternomastoid fascia on the lateral surface of the mastoid. Lymph 
nodes are also found on the anterior surface of the mastoid. The 
lymphatics  that  traverse  the  insertion  of  sternomastoid 
communicate with the deep cervical chain on the deep surface of 
the  muscle  immediately  inferior  to  the  mastoid  bone.  191 
Table 26 – Lymph node basins involved with metastatic spread 
Lead Author 
Total Number of Cases 
With Metastases 
Post-Auricular / 
Mastoid  Parotid  Upper Cervical  Neck Other Levels 
Byers  79  12 (15.2%)  35 (44.3%)  28 (35.4%)  4 (5.0%) 
Freedlander  29    14 (48.3%)  15 (51.7%)   
Leferink  4  1 (25%)  2 (50%)  1 (25%)   
Clark  24  7 (29.2%)  13 (54.2%)  10 (41.7%)  4 (16.7%) 
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Discussion 
Since  lymphatic  metastases  commonly  affect  both  the  parotid 
gland and cervical chains it cannot be assumed that the presence 
of disease in one of these basins is an indication that the other is 
not affected and both must be resected. This study suggests that a 
therapeutic  neck  dissection  for  tumours  arising  on  the  auricle 
should include the parotid gland superficial, inferior and posterior 
to the facial nerve. The parotid should be removed with the fascia 
and overlying superficial lymph nodes (Figure 46) and the greater 
auricular nerve will be sacrificed. The post-auricular and mastoid 
nodal groups should be removed by clearing the mastoid bone on 
the  anterior,  lateral  and  inferior  surfaces  to  the  sub-periosteal 
plane, as this will ensure complete removal of all lymphatic tissue.  
In cases where there is gross evidence of disease in this area it 
may be desirable to remove the mastoid process to ensure tumour 
free  resection  margins.  The  only  way  to  ensure  the  complete 
clearing of the peri-mastoid lymph nodes is to remove the upper 
portion  of  sternocleidomastoid  muscle  with  overlying  superficial 
cervical nodes. Level IIa and Iib (Figure 47) need to be cleared in 
their entirety from the stylohyoid anteriorly to the posterior border 
of sternocleidomastoid and from the skull base to the level of the 
hyoid  bone  inferiorly.  The  accessory  nerve  and  internal  jugular 
vein should be preserved unless they are felt to be compromised 
by disease. Levels I and III to V of the neck can then be cleared in 
a standard fashion.
113 
Skin incisions for neck dissections are a matter of debate.
113 It is 
our preference for this operation to use an incision which starts 
anterior to the helical root runs down in front of the tragus to the 
earlobe  and  then  into  the  port-auricular  sulcus.  The  incision  is   193 
carried on to the superior margin of the mastoid process before 
curving posteriorly and then inferiorly to run along and in line with 
the  centre  of  the  sternocleidomastoid  muscle  before  running 
anteriorly at least 2cm below the mandible in a skin crease and 
onto  the  midpoint  of  the  mandible.  A  flap  is  raised  in  the 
subcutaneous  plane  anteriorly  above  the  superficial  cervical 
nodes. The upper posterior portion of this flap is often trimmed 
before it is re-inset at the end of the procedure. This area of skin 
that  is  trimmed  is  the  skin  that  would  have  been  overlying  the 
lateral surface of the mastoid bone and its removal gives further 
reassurance that no post-auricular lymph nodes have been missed 
in  the  subcutaneous  tissue.  A  second  incision  is  made  running 
inferiorly  from  this  incision  to  the  clavicle  to  form  a  tri-radiate 
incision.  This  allows  access  to  the  lower  levels  of  the  neck.  No 
matter  what  type  of  incision  is  used  it  should  take  into 
consideration the fact that there will be exposed mastoid bone at 
the  end  of  the  procedure  and  good  quality  coverage  of  this  is 
required to prevent wound breakdown and subsequent exposed 
bone especially if post-operative radiotherapy is being considered. 
Based  on  our  results  an  elective  or  staging  neck  dissection  for 
auricular  tumours  should  include  the  superficial  parotid  gland, 
level II, mastoid and post-auricular nodes as described above. The 
indications for such a procedure remain unclear but it may be that 
on an individual case it could be justified. Such a procedure would 
need to be undertaken in the knowledge that therapy would need 
to  be  directed  to  levels  I  and  III  to  V  of  the  neck  if  metastatic 
disease was found on histopathological processing. 
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Figure 48 - Illustration of superficial level lymph nodes 
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Figure 49 - Illustration of deep level lymph nodes 
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General Discussion 
Summary of Findings 
In this thesis we have examined possible strategies that could be 
used  at  the  time  of  initial  diagnosis  of  auricular  squamous  cell 
carcinoma to direct therapy to the regional lymph nodes basins. 
The two approaches taken have been to identify tumours most at 
risk of metastatic spread and to detect early metastatic spread. It is 
clear from the sentinel node study that although the technique may 
be possible, it should not be routinely used in clinical practice. The 
reasons for this are due to the difficulty in identifying patients most 
at  risk  of  metastatic  spread  which  makes  the  complication  rate 
unacceptably  high.  This  is  in  contrast  to  other  head  and  neck 
cancers where the technique is used to lower the morbidity of a 
neck  dissection  which  is  generally  applied  to  tumours  with  a 
greater than 20% metastatic risk. 
In  the  systematic  review  several  authors  have  recognised  the 
problem  caused  by  lymphatic  metastasis  and  tried  to  devise 
criteria  to  direct  prophylactic  therapy  to  the  neck.  Unfortunately 
there has been no clear consensus of opinion as to when this is 
warranted. There is no published work where elective lymph node 
dissections have been carried out to validate their use. Our own 
retrospective analysis has added to this information and the use of 
a measured depth of invasion rather than Clark’s levels seems to 
provide a more useful method by which high-risk tumours can be 
identified. In combination with the adverse histological features of 
lymphatic  invasion,  cartilage  destruction  and  a  non-cohesive 
invasive front it is possible to identify tumours with a sufficiently 
high metastatic rate to warrant intervention to the regional lymph 
nodes.   197 
The anatomical study and the sentinel node study have shown that 
first echelon nodes can lie in the post-auricular/mastoid, parotid 
or  level  II  neck  nodes.  There  are  several  anastamotic  pathways 
around  the  post-auricular/  mastoid  nodes  that  could  permit 
embolic tumour cells to bypass them. These areas must be treated 
fully if any prophylactic therapy to the neck is to be of benefit. It is 
known from the retrospective study and the systematic review that 
once disease is present at one of the first echelon locations it can 
spread to levels I and III to V of the neck.  
It should also be emphasised that where completeness of primary 
excision is doubtful, further excision should be carried out. 
Strengths and Weaknesses 
There is as yet no evidence that early intervention to the lymph 
nodes is of advantage to patients. On the other hand the evidence 
available  from  the  review  shows  that  prognosis  is  poorer  once 
more than one node is involved and there is evidence of extra-
capsular  spread.  Also  the  majority  of  patients  who  die  of  this 
disease do so as a result of failure of loco-regional control. Early 
and directed intervention as suggested in the neck dissection study 
should  be  able  to  provide  better  loco-regional  control  and 
improve  outcome.  However  given  the  age  group  of  patients 
involved such intervention is likely to carry a significant morbidity. 
The  place  of  sentinel  lymph  node  biopsy  in  treatment  of  this 
malignancy  is  not  yet  clear.  It  has  not  yet  demonstrated  early 
detection of lymphatic metastasis and therefore its use cannot be 
justified outside a clinical trial.   198 
Meaning Of The Thesis 
There  is  now  evidence  to  identify  auricular  squamous  cell 
carcinomas with a sufficiently high metastatic potential to warrant 
intervention  to  the  regional  lymph  nodes,  specifically  the  nodal 
basins  at  highest  risk  of  metastatic  spread.  Patients  with  these 
lesions  should  in  future  be  considered  for  a  lymphadenectomy 
procedure  and/or  radiotherapy.  The  current  policy  of  treatment 
only when metastasis becomes clinically apparent carries a high 
mortality. 
A staging or elective neck dissection for auricular squamous cell 
carcinoma  should  include  the  superficial  parotid  gland,  post-
auricular/mastoid  and  level  II  nodes.  Treatment  should  be 
extended to levels I and III to V of the neck once there is evidence 
of lymph node metastasis.   199 
Unanswered Questions And Future Research 
Future research should concentrate on establishing the cost and 
benefits associated with early intervention to the regional lymph 
nodes in high risk cases of  auricular squamous  cell  carcinoma. 
Ideally  a  randomised  trial  would  divide  patients  between  a 
prophylactic neck dissection and a wait and see policy. However 
given the number of patients likely to be enrolled in such a study it 
will be difficult to obtain a sufficient number to allow a meaningful 
analysis to be carried out. Our unit has only seen 50 cases over a 
12 year period that would be regarded as high risk and many of 
these  would  likely  be  excluded  from  a  trial  because  of  co-
morbidities. 
An  observational  study  where  all  patients  sufficiently  well  to 
undergo neck dissection were offered this if they had a high risk 
tumour  would  be  able  to  provide  information  on  the  costs  and 
benefits of this procedure and establish if the metastatic rate in this 
group of tumours is as high as expected. 
It is now clear how extensive an elective or staging neck dissection 
should  be.  It  is  easy  to  argue  the  case  for  only  resecting  the 
superficial  parotid  gland,  post-auricular/mastoid  and  level  II 
nodes as this keeps the surgical procedure to a minimum and will 
provide staging information. However if metastases were detected 
in this specimen further treatment would need to be given to the 
rest of the neck either in the form of a completion neck dissection 
or radiotherapy. Such further treatment would be expected to be 
necessary in about 1 in 3 cases.  
Sentinel  lymph  node biopsy  remains  a  potentially  useful  tool  in 
auricular squamous cell carcinoma although it now needs to be 
evaluated  as  a  staging  tool  in  comparison  to  a  staging  neck 
dissection.  Such  evaluation  could  be  carried  out  in  conjunction   200 
with an observational study of elective neck dissections. Sentinel 
lymph nodes could be identified and harvested at the start of an 
elective  lymph  node  dissection  and  then  undergo  histological 
examination.  If  the  procedure does  correctly  identify  nodes  with 
early metastatic spread then its use could be justified in place of 
elective lymph node dissection.   201 
Conclusions 
Auricular squamous cell carcinoma is known to metastasise to the 
regional lymph nodes in about 11% of cases. The development of 
metastasis is an adverse prognostic indicator and the majority of 
patients in whom they develop will subsequently die usually as a 
result  of  failure  of  loco-regional  control.  The  current  treatment 
policy  for  these  tumours  is  to  wait  for  clinical  evidence  of 
metastatic  spread  before  treatment  of  the  lymph  node  basins 
because  there  has  been  insufficient  evidence  to  define  which 
tumours are of sufficiently high risk to warrant elective intervention. 
Recent  work  has  shown  that  tumours  at  high-risk  of  metastatic 
spread have a depth of invasion over 8mm or a depth of invasion 
between  2  –  8mm  and  evidence  of  cartilage  destruction, 
lymphovascular  invasion  or  a  non-cohesive  invasive  front.  The 
metastatic rate in these groups of tumours is 34.7%. 
Treatment of established metastases in the regional lymph node 
basins is difficult because of the proximity to vital structures around 
the base of skull. This makes surgical clearance by means of a 
neck  dissection  to  clear  all  draining  lymph  nodes  difficult  to 
achieve.  However  surgical  clearance  of  sub-clinical  deposits  by 
means of an elective lymph node dissection of specific lymph node 
groups should be more easily carried out as the locations of the 
lymph nodes where disease will first present and spread from is 
now documented. It is not yet established if elective lymph node 
dissections  for  auricular  squamous  cell  carcinoma  carries  a 
survival  benefit  to  the  patient  and  a  cost  benefit  analysis  is 
required to support its routine clinical use. 
Sentinel lymph node biopsy can provide accurate information on 
specific  lymph  nodes  draining  primary  auricular  neoplasms  but 
needs  further  evaluation  before  it  can  be  accepted  into  routine   202 
clinical practice. It would be possible to evaluate this at the same 
time as performing elective neck dissections.   203 
Appendix 1 – Ethical Considerations 
Both the retrospective review and the sentinel node trial required 
approval from an ethics committee. This was obtained from the 
local  ethics  committee  at  Glasgow  Royal  Infirmary.  The  sentinel 
node  trial  required  Patient  Information  Sheet,  GP  Information 
Sheets and consent forms. These are appended on the following 
pages. 
   204 
PATIENT INFORMATION FORM 
Version 2 29
th July 2004 
 
TITLE OF PROJECT:  
Early detection of spread of skin cancer of the ear 
 
INVITATION 
You  are  being  invited  to  take  part  in  a  research  study.    Before  you 
decide it is important for you to understand why the research is being 
done and what it will involve.  Please take time to read the following 
information carefully and discuss it with others if you wish.  Ask us if 
there is anything that is not clear or if you would like more information.  
Take time to decide whether or not you wish to take part. Thank you for 
reading this. 
 
What is the purpose of the study? 
We  are  always  looking  for  ways  to  improve  the  treatment  and 
investigations  we  offer  people.  Currently,  we  are  performing  a  new 
technique to determine whether we can make improvements to the care 
of patients with cancer of their ear. We would like to invite you to enter 
a  clinical  trial  of  a  procedure  called  ‘Sentinel  lymph  node  biopsy’. 
Lymph nodes are small glands in your neck and near your ear which 
drain fluid away from the tissues of your body. They are commonly 
referred to as lymph glands. The ‘sentinel lymph node’ is the first place 
to which we believe the cancer would spread before it spreads anywhere 
else. Sentinel lymph node biopsy is a procedure that has been performed 
for patients since the early 1990’s. In patients with other types of cancer 
it has been shown to be a very good way of telling whether spread of the 
cancer has occurred or not. 
 
Cancer of the ear usually spreads through the lymphatic channels (small 
tubes which drain fluid from all the areas of the body) to lymph nodes. 
In patients with cancer of the ear, we always examine the lymph nodes 
in the neck for signs of spread. This relies on the cancer having spread 
and  then  grown  large  enough  to  be  felt  under  the  skin.  The  earliest 
spread is not always detectable by this method since the lymph nodes 
may  not  be  big  enough  to  feel.  If  we  can  detect  enlarged  nodes  we 
perform an operation called a ‘neck dissection’. This is an operation to 
remove  a  large  proportion  of  the  lymph  nodes  in  the  neck  and  is 
considered major surgery. Since major surgery carries some risks, we 
are reluctant to perform neck dissections on patients whom we think 
will not benefit from it.  
 
In  your  case,  we  will  not  be  performing  a  ‘neck  dissection’  at  the 
moment, because we cannot yet detect any cancer in your neck. Our 
normal practice for patients, such as you, is to observe and examine you 
every few months. By doing this, if spread has occurred we will be able 
to detect this early, and give you the treatment you need quickly. 
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Why have I been chosen? 
You  have  been  chosen  because  you  have  cancer  of  the  ear  and  we 
cannot detect any spread by examining your neck. 
 
Do I have to take part? 
It is up to you to decide whether or not to take part.  If you do decide to 
take part you will be given this information sheet to keep and be asked 
to sign a consent form. If you decide to take part you are still free to 
withdraw  at  any  time  and  without  giving  a  reason.    A  decision  to 
withdraw at any time, or a decision not to take part, will not affect the 
standard of care you receive. 
 
What will happen to me if I take part? 
Sentinel node biopsy is a technique that involves two injections and a 
small operation under general anaesthesia. This may be combined with 
the surgery to your ear or may mean an additional operation. One of 
these injections will be given while you are awake and one while you 
are under anaesthesia. The first injection is given into the ear and the 
substance  injected  is  a  radioactive.  This  then  travels  to  the  ‘sentinel 
node’ through the lymphatic channels. The injection will be given in the 
Nuclear  Medicine  Department  at  the  Royal  Infirmary.  The  dose  of 
radioactivity used is very low. After the injection, a picture will be of 
your neck with a special camera which will show us where the sentinel 
lymph node is. The scan takes about half an hour to one hour in total. 
 
The second injection is given while you are asleep under anaesthesia. 
The injection given is a blue dye and colours the lymph channels and 
lymph nodes blue. When we perform a sentinel node biopsy, we can 
find  blue  stained  lymph  nodes  and  trace  radioactivity  with  a  special 
probe to find the sentinel node. The sentinel nodes are sent to be looked 
at under a microscope. If any tumour is seen in the sentinel node, we 
will offer you further treatment to the lymph nodes in the neck. 
 
What do I have to do? 
If there is any possibility that you are pregnant you should inform us 
immediately and not take part in this study. 
 
What are the alternatives for diagnosis or treatment? 
Standard treatment would be to examine your neck every few months in 
the clinic for signs of spread and offer surgery if spread was detected. 
 
What are the side effects of taking part? 
Sentinel node biopsy has been performed for several years, and there are 
very few side effects associated with it. These are: 
1.  Blue staining of the urine. Since we inject blue dye into the tissues 
around your tumour, and since the dye is removed by your kidneys, 
for about one day after your operation, your urine will be stained 
blue.   206 
2.  Hypersensitivity. There have been a few reports of people being 
allergic to the blue dye we inject. This is more common in people 
who suffer allergies to other things. If you tend to suffer from 
allergies, please let us know. 
 
What are the possible disadvantages and risks of taking part? 
Your  surgery  and  anaesthetic  will  be  slightly  longer  than  would 
normally be the case and you will have a small additional scar. For some 
patients it will mean an additional operation. 
 
What are the possible benefits of taking part? 
If you agree to take part in this research project it may be of little or no 
benefit  to  you  but  the  results  may  help  other  patients  in  the  future. 
Should you not wish to take part in the project or at any time should you 
wish to stop taking part, you may do so. The care which you receive and 
your proposed treatment protocol will not be affected in any way. If you 
agree to take part in this research project, your own general practitioner 
will be told and will be given detailed information about the care you 
will receive. Should you require more detailed information concerning 
this project, please do not hesitate to ask and we will provide a more 
detailed description of the project. By agreeing to enter our trial, you are 
agreeing to have a sentinel node biopsy performed. The rest of your 
treatment and investigations will be performed according to our usual 
schedule.  Sentinel  node  biopsy  is  an  investigation  which  will  be 
performed in addition to your usual treatment. Since it is an unproven 
theory in squamous cell cancer of the ear, we cannot guarantee that it 
will be successful in identifying cancer spread. 
 
What if new information becomes available? 
Sometimes  during  the  course  of  a  research  project,  new  information 
becomes available about the treatment/drug that is being studied.  If this 
happens, your research doctor will tell you about it and discuss with you 
whether you want to continue in the study.  If you decide to withdraw 
your research doctor will make arrangements for your care to continue.  
If you decide to continue in the study you will be asked to sign an 
updated consent form. 
 
What happens when the research study stops? 
You will continue to be seen in clinic as we normal would for someone 
with  squamous  cell  carcinoma  of  the  ear  and  offer  you  any  further 
treatment that may be required. 
 
What if something goes wrong? 
If you are harmed by taking part in this research project, there are no 
special  compensation  arrangements.    If  you  are  harmed  due  to 
someone's negligence, then you may have grounds for a legal action but 
you may have to pay for it.  Regardless of this, if you wish to complain, 
or  have  any  concerns  about  any  aspect  of  the  way  you  have  been 
approached  or  treated  during  the  course  of  this  study,  the  normal   207 
National  Health  Service  complaints  mechanisms  may  be  available  to 
you. 
 
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the 
research will be kept strictly confidential.  Any information about you 
which  leaves  the  hospital/surgery  will  have  your  name  and  address 
removed so that you cannot be recognised from it. Your GP will be 
informed of your participation in this trial. 
 
What will happen to the results of the research study? 
The results of the study will be published in scientific journals. You will 
not be identified in any way in the published material. 
 
Who is organising and funding the research? 
The research is being organised by Canniesburn Plastic Surgery Unit 
and funded by charities and endowments. 
 
FURTHER INFORMATION 
If  you  or  your  family  have  any  questions  are  require  any  further 
information,  please  contact:  Mr  R.  Clark  (Head  and  Neck  Research 
Fellow) or Mr D.S. Soutar (Consultant Plastic Surgeon) at Canniesburn 
Plastic Surgery Unit, Glasgow Royal Infirmary, Glasgow G4 0SF. Tel 
0141 211 5776   208 
GP INFORMATION FORM (Version 1, 30
th June 2004) 
Your patient has agreed to be included in this study. 
 
TITLE OF PROJECT:  
Sentinel  node  biopsy  to  upstage  clinically  false  negative  necks  in  patients  with 
squamous cell cancer of the ear 
 
INTRODUCTION 
Squamous cell cancer spreads by the lymphatic channels to lymph nodes located in the 
neck. In patients with squamous cell cancer of the ear, we always examine the neck for 
signs  of  metastases  and  if  spread  has  occurred  we  would  usually  perform  a  neck 
dissection. Since a neck dissection is major surgery and carries some risks, we usually 
do not perform neck dissections on patients whom we think will not benefit from it. At 
the moment, however, the only way of determining whether spread to the neck has 
occurred or not is to perform a neck dissection and sometimes we perform a neck 
dissection for the sole reason to find out if spread has occurred or not. 
In your patient’s case, we will not be performing a neck dissection at the moment, 
because we feel that spread to the lymph nodes has not occurred. Our normal practice 
for such patients, is to observe and examine you every few months.  
We are always looking for ways to improve the treatment and investigations we offer 
people. Currently, we are performing a new technique to determine whether we can 
make improvements to the care of patients with squamous cell cancer called “Sentinel 
node biopsy”. 
Sentinel node biopsy is a procedure that has been performed for patients since the 
early 1990’s. In patients with malignant melanoma (a type of skin cancer) and breast 
cancer, sentinel node biopsy has been shown to be a very good way of telling whether 
spread of the cancer has occurred or not. We would like to see if sentinel node biopsy 
can tell us whether spread has occurred in patients with squamous cell cancer of the 
ear. 
Sentinel  node  biopsy  is  a  technique  that  involves  two  injections  both  around  the 
tumour  to  help  localise  the  target  lymph  node.  The  first  injection  is  a  radioactive 
protein given in the Nuclear Medicine Department at the Royal Infirmary. The dose of 
radioactivity  used  is  very  low  in  comparison  to  the  doses  we  use  for  other 
investigations  in  Nuclear  Medicine  (0.4mSv).  The  sentinel  nodes  are  sent  to  the 
pathology laboratory and examined for the presence of tumour cells. If any tumour is 
seen in the sentinel node, we will offer further treatment to the lymph nodes in the 
neck. 
The rest of your patient’s treatment and investigations will be performed according to 
our usual schedule. Sentinel node biopsy is an investigation which will be performed 
in addition to the usual treatment. Since it is an unproven theory in squamous cell 
cancer, we cannot guarantee that it will be successful in identifying metastatic spread. 
 
SIDE EFFECTS 
Sentinel node biopsy has been performed for several years, and there are very few side 
effects associated with it. These are: 
1.  Blue staining of the urine for a few days. Patent blue is renally excreted 
2.  Hypersensitivity. There have been a few reports of people being allergic to 
the blue dye we inject. This is more common in people who suffer allergies to 
other things. If you tend to suffer from allergies, please let us know. 
 
BENEFITS TO YOUR PATIENT 
Agreeing to take part in this research project it may be of little or no benefit to your 
patient but the results may help other patients in the future. Should they not wish to 
take part in the project or at any time wish to stop taking part, they may do so. The 
care which they receive and proposed treatment protocol will not be affected in any 
way. 
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FURTHER INFORMATION 
If you have any questions or require any further information, please contact: 
Mr R. Clark (Head and Neck Research Fellow) or Mr D.S. Soutar (Consultant Plastic 
Surgeon) at Canniesburn Plastic Surgery Unit.   210 
Study Number: 04/S0705/24 
Patient Identification Number for this trial: 
 
CONSENT FORM 
 
Title of Project: Early detection of spread of skin cancer of the 
ear 
 
Name of Researcher:  
 
      Please initial box 
 
1.  I confirm that I have read and understand the information 
       sheet dated 30 June 2004 (version 1 ) for the above study and  
  have had the opportunity to ask questions. 
 
2.  I understand that my participation is voluntary and that I am free 
to     
  withdraw  at  any  time,  without  giving  any  reason,  without  my 
medical  
  care or legal rights being affected. 
 
3.  I understand that sections of any of my medical notes may be 
looked      
  at by responsible individuals from regulatory authorities where 
  it is relevant to my taking part in research.  I give permission for 
  these individuals to have access to my records. 
 
4.    I agree to take part in the above study.             
 
 
 
                     
Name of Patient  Date  Signature 
 
       
Name of Person taking consent    Date  Signature 
(if different from researcher) 
 
     
Researcher  Date  Signature 
 
 
1 for patient; 1 for researcher; 1 to be kept with hospital notes 
 
 
Form Version 2 29
th July 2004   211 
Appendix  2  –  Neck  Dissection 
Terminology 
There has been a great deal of variation in the approach to neck 
dissection  over  the  past  few  decades  and  as  a  result  the 
terminology has changed. The description of specific nodal groups 
or chains has given way to the concept of levels as an increasing 
amount  of  evidence  became  available  to  establish  patterns  of 
nodal spread of disease. These levels are well defined anatomical 
regions  and  the  development  of  this  terminology  has  allowed 
consistent reporting and management of disease. The American 
Head  and  Neck  Society  and  the  American  Academy  of 
Otolaryngology  –  Head  and  Neck  Surgery  published  the  last 
update of the classification of neck dissection in 2002.
114 There 
revisions are widely accepted and are used throughout this thesis. 
 
Lymph  Node  Groups  Found  Within  the  6  Levels 
and the 6 Sublevels 
Submental (sublevel IA) 
Lymph nodes within the triangular boundary of the anterior belly 
of the digastric muscles and the hyoid bone. These nodes are at 
greatest risk for harboring metastases from cancers arising from 
the  floor  of  mouth,  anterior  oral  tongue,  anterior  mandibular 
alveolar ridge, and lower lip. 
Submandibular (sublevel IB) 
Lymph  nodes  within  the  boundaries  of  the  anterior  belly  of  the 
digastric  muscle,  the  stylohyoid  muscle,  and  the  body  of  the 
mandible.  It  includes  the  preglandular  and  the  postglandular 
nodes  and  the  prevascular  and  postvascular  nodes.  The   212 
submandibular gland is included in the specimen when the lymph 
nodes  within  the  triangle  are  removed.  These  nodes  are  at 
greatest risk for harboring metastases from cancers arising from 
the oral cavity, anterior nasal cavity, soft tissue structures of the 
midface, and submandibular gland. 
Upper jugular (includes sublevels IIA and IIB) 
Lymph  nodes  located  around  the  upper  third  of  the  internal 
jugular vein and adjacent spinal accessory nerve extending from 
the level of the skull base (above) to the level of the inferior border 
of the hyoid bone (below). The anterior (medial) boundary is the 
stylohyoid  muscle  (the  radiologic  correlate  is  the  vertical  plane 
defined by the posterior surface of the submandibular gland) and 
the  posterior  (lateral)  boundary  is  the  posterior  border  of  the 
sternocleidomastoid  muscle.  Sublevel  IIA  nodes  are  located 
anterior  (medial)  to  the  vertical  plane  defined  by  the  spinal 
accessory nerve. Sublevel IIB nodes are located posterior (lateral) 
to the vertical plane defined by the spinal accessory nerve. The 
upper jugular nodes are at greatest risk for harboring metastases 
from  cancers  arising  from  the  oral  cavity,  nasal  cavity, 
nasopharynx,  oropharynx,  hypopharynx,  larynx,  and  parotid 
gland. 
Middle jugular (level III)  
Lymph  nodes  located  around  the  middle  third  of  the  internal 
jugular vein extending from the inferior border of the hyoid bone 
(above) to the inferior border of the cricoid cartilage (below). The 
anterior (medial) boundary is the lateral border of the sternohyoid 
muscle, and the posterior (lateral) boundary is the posterior border 
of  the  sternocleidomastoid  muscle.  These  nodes  are  at  greatest 
risk for harboring metastases from cancers arising from the oral 
cavity, nasopharynx, oropharynx, hypopharynx, and larynx.   213 
Lower jugular (level IV)  
Lymph nodes located around the lower third of the internal jugular 
vein  extending  form  the  inferior  border  of  the  cricoid  cartilage 
(above) to the clavicle below. The anterior (medial) boundary is 
the  lateral  border  of  the  sternohyoid  muscle  and  the  posterior 
(lateral)  boundary  is  the  posterior  border  of  the 
sternocleidomastoid muscle. These nodes are at greatest risk for 
harboring metastases from cancers arising from the hypopharynx, 
thyroid, cervical esophagus, and larynx. 
Posterior triangle group (includes sublevels VA and VB) 
This group is composed predominantly of the lymph nodes located 
along  the  lower  half  of  the  spinal  accessory  nerve  and  the 
transverse  cervical  artery.  The  supraclavicular  nodes  are  also 
included in posterior triangle group. The superior boundary is the 
apex  formed  by  convergence  of  the  sternocleidomastoid  and 
trapezius muscles, the inferior boundary is the clavicle, the anterior 
(medial)  boundary  is  the  posterior  border  of  the 
sternocleidomastoid muscle, and the posterior (lateral) boundary is 
the  anterior  border  of  the  trapezius  muscle.  Sublevel  VA  is 
separated  from  sublevel  VB  by  a  horizontal  plane  marking  the 
inferior  border  of  the  anterior  cricoid  arch.  Thus,  sublevel  VA 
includes the spinal accessory nodes, whereas sublevel VB includes 
the  nodes  following  the  transverse  cervical  vessels  and  the 
supraclavicular  nodes  with  the  exception  of  the  Virchow  node, 
which is located in level IV. The posterior triangle nodes are at 
greatest risk for harboring metastases from cancers arising from 
the  nasopharynx,  oropharynx,  and  cutaneous  structures  of  the 
posterior scalp and neck. 
Anterior compartment group (level VI)   214 
Lymph  nodes  in  this  compartment  include  the  pretracheal  and 
paratracheal  nodes,  precricoid  (Delphian)  node,  and  the 
perithyroidal nodes including the lymph nodes along the recurrent 
laryngeal  nerves.  The  superior boundary  is  the  hyoid  bone,  the 
inferior  boundary  is  the  suprasternal  notch,  and  the  lateral 
boundaries are the common carotid arteries. These nodes are at 
greatest risk for harboring metastases from cancers arising from 
the  thyroid  gland,  glottic  and  subglottic  larynx,  apex  of  the 
piriform sinus, and cervical esophagus. 
 
Classification of Neck Dissection 
RADICAL NECK DISSECTION 
Radical  neck  dissection  refers  to  the  removal  of  all  ipsilateral 
cervical lymph node groups extending from the inferior border of 
the  mandible  to  the  clavicle,  from  the  lateral  border  of  the 
sternohyoid muscle, hyoid bone, and contralateral anterior belly of 
the  digastric  muscle  medially,  to  the  anterior  border  of  the 
trapezius  muscle.  Included  are  all  lymph  nodes  from  levels  I 
through  V.  The  SAN,  internal  jugular  vein,  and  SCM  are  also 
removed. Radical neck dissection does not include removal of the 
suboccipital nodes, periparotid nodes (except intraparotid nodes 
located  in  the  posterior  aspect  of  the  submandibular  triangle), 
buccinator  nodes,  retropharyngeal  nodes,  and  midline  visceral 
(anterior compartment) nodes. 
 
MODIFIED RADICAL NECK DISSECTION 
Modified radical neck dissection refers to the excision of all lymph 
nodes  routinely  removed  by  the  radical  neck  dissection  with   215 
preservation of 1  or more nonlymphatic structures (ie, the SAN, 
internal jugular vein, and SCM). The structure(s) preserved should 
be specifically named (eg, modified radical neck dissection with 
preservation of the SAN). 
 
SELECTIVE NECK DISSECTION 
Selective neck dissection refers to a cervical lymphadenectomy in 
which there is preservation of 1 or more of the lymph node groups 
that  are  routinely  removed  in  the  radical  neck  dissection.  The 
lymph  node  groups  removed  are  based  on  the  patterns  of 
metastases, which are predictable relative to the primary site of 
disease. For oral cavity cancers, the lymph nodes at greatest risk 
are located in levels I, II, and III. The lymph nodes at greatest risk 
for  oropharyngeal,  hypopharyngeal,  and  laryngeal  cancers  are 
located  in  levels  II,  III,  and  IV,  whereas  for  thyroid  cancer,  the 
lymph nodes in VI are at the greatest risk. 
 
EXTENDED NECK DISSECTION 
Extended  neck  dissection  refers  to  the  removal  of  1  or  more 
additional lymph node groups or nonlymphatic structures, or both, 
not encompassed by the radical neck dissection. Examples of such 
lymph node groups include the parapharyngeal (retropharyngeal), 
superior  mediastinal,  perifacial  (buccinator),  and  paratracheal 
lymph  nodes.  Examples  of  nonlymphatic  structures  include  the 
carotid  artery,  hypoglossal  nerve,  vagus  nerve,  and  paraspinal 
muscles. All additional lymphatic and/or nonlymphatic structure(s) 
to be removed should be identified in parentheses. 
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